Amendment No. 2 to 2005 Year End Report
 

 
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
____________________________
 
FORM 10-KSB
Amendment No. 2
____________________________
/X/ Annual Report under Section 13 or 15(d) of the Securities Exchange Act of 1934
 
 For the fiscal year ended December 31, 2005

/ / Transition report under Section 13 or 15(d) of the Securities Act of 1934
 
For the transition period from _______ to _______

Commission file number: 0-22413

UNIVEC, INC.
(Name of Small Business Issuer in its Charter)

Delaware
11-3163455
(State or Other Jurisdiction of
(I.R.S. Employer
Incorporation or Organization)
Identification No.)
 
____________________________
 
822 Guilford Avenue, Suite 208, Baltimore, MD 21202
(410) 347-9959
(Address and telephone number of principal executive office)
 
____________________________
 
Former address: 4810 Seton Drive, Baltimore, MD 21215
(Former name, former address, and former fiscal year, if changed since last report)
 
Securities registered under Section 12(b) of the Exchange Act: None

Securities registered under Section 12(g) of the Act:

Title of Class
Common Stock, $.001 par value
____________________________

 

 
Check whether the issuer: (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes /X/ No / / 

Check if there is no disclosure of delinquent filers in response to Item 405 of Regulation S-B contained in this form, and no disclosure will be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-KSB Amendment No. 2 or any other amendment to this Form 10-KSB. /X/

Revenues for the issuer's most recent fiscal year were $81,398.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [ ] Yes [X] No 

The aggregate market value of the voting stock held by non-affiliates computed by reference to the closing price at which the stock was sold on December 31,  2005 was $1,144,602.
 
____________________________
 
ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS
DURING THE PAST FIVE YEARS

Check whether the issuer has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Exchange Act after the distribution of securities under a plan confirmed by a court. Yes / / No / /

APPLICABLE ONLY TO CORPORATE REGISTRANTS

As of December 31, 2005 the issuer had 57,230,128 shares of common stock, $.001 par value, outstanding.

DOCUMENTS INCORPORATED BY REFERENCE
None


-1-





Part I

Item 1. Description of Business.

UNIVEC, Inc. ("UNIVEC" or "the Company") is an integrated licensing, manufacturing, and marketing company dedicated to providing safer health products to patients and caregivers worldwide. Univec also assists pharmaceutical companies in marketing, fulfillment, and tracking drug samples. Univec produces auto-disable and safety syringes. The Company is a Delaware corporation incorporated on October 7, 1996, and the successor by merger to UNIVEC, Inc., a New York corporation, incorporated on August 18, 1992.

On December 31, 2001 Univec, Inc., acquired Physician and Pharmaceutical Services, Inc., (PPSI) a company engaged in group purchasing (GPO) and promoting Pharmaceutical company prescription samples to physicians for their patients. PPSI reduces the cost in the prescription-sampling channel by providing efficient fulfillment and tracking of prescription usage. PPSI's national network of pharmacies fills the sample prescription on a discounted fee and the Company's mail service fulfillment complements additional needs. PPSI's approach conforms to regulations requiring increased accountability and elimination of diversion of prescription samples, consequently reducing the exposure of physicians and pharmaceutical companies to potential liabilities and non-compliance penalties. PPSI’s group purchasing programs provide for reduces prices on prescription drugs and other products through leveraged purchasing and closed system market share. Univec also is a distributor of a highly regulated pharmaceutical drug, methadone and other prescription drug products.

Univec during late 2004 established the company as a distributor of specialty and highly regulated pharmaceutical products. The company intends to expand the product line to take further advantage of its group purchasing and closed systems purchasing.

Univec extended its product line to include a highly regulated pharmaceutical (methadone) and other pharmaceutical products. The company will continue to sell it products through large United States based wholesalers as well as direct in large bulk to the larger customers of the company. The company’s group purchase programs and closed market purchasing positions the company’s product line well.
 
In 1997, Univec commenced production and sales of its 1cc Auto-Disable Syringes (AD-syringes), which are designed to make accidental or deliberate reuse difficult. The accidental or deliberate reuse of syringes is a frequent cause of the spread of the human immunodeficiency ("HIV") and hepatitis viruses, as well as other blood-borne pathogens. Univec has received 510(k) clearance from the U.S. Food and Drug Administration (the "FDA") to market it's AD-Syringes in the United States.

Univec believes that its 1cc difficult-to-reuse syringes are more effective than competitive syringes and that they are competitively priced. Univec also believes that it is the only company that markets an AD-Syringe with a 1cc barrel, which is ideal for dispensing accurate dosages of medicine (e.g., allergy, immunization and insulin medicines). It is more difficult to deliver up to a .95cc dosage accurately with a syringe barrel that is greater than 1cc. Univec does not know of any other company that offers a lcc aspirating syringe that can be locked. Healthcare workers need aspirating syringes to mix medications in the syringe barrel and inject medications intravenously. Furthermore, Univec believes that aspirating syringes are preferred by diabetes patients and needle-exchange programs. Pursuant to programs of international relief agencies, Univec has shipped its lcc AD-Syringes to over 80 countries.

-2-






Univec also manufactures and markets patented Sliding Sheath Syringes designed to protect patients and healthcare workers from needle stick injuries, in compliance with the Federal Needlestick Safety and Prevention Act of the United States government, and requirements of the Occupational Safety and Health Administration (OSHA). Univec has FDA approval for an extendible barrel sleeve syringe used in the sliding sheath syringes based on technology licensed by Univec.
 
In addition, Univec has developed a Bifurcated Needle Safety Syringe specifically designed to comply with the Federal Needlestick Safety and Prevention Act of the United States government. Univec has been granted 510(k) clearance by the FDA. The device is intended for use in administering smallpox vacines in response to potential bio-terrorist threats. The Needlestick Safety mandate requires all U.S. healthcare providers to evaluate and implement safer medical devices under their OSHA "Exposure Control Plans". All healthcare providers must now adopt safer devices to protect workers and others from needles potentially contaminated with blood borne pathogens such as hepatitis B, hepatitis C, and HIV.

In general, this "safer device" rule applies in the normal course of operations, as well as in connection with any mass immunization program authorized by the federal government.

Univec markets its AD-Syringes and Sliding Sheath Safety Syringes to governments of developing countries, provided that such syringes are manufactured in the United States, private hospitals and health facilities in the United States, and distributors in the United States.

In developing countries, accidental or deliberate reuse of disposable syringes poses a serious risk of transmitting HIV-AIDS, hepatitis and other blood-borne pathogens. Relief agencies, including UNICEF and WHO, administered almost a billion immunizations to women and children through immunization programs in developing countries in 1998 and anticipate administering 3.5 billion immunizations by 2005. WHO reported that surveys carried out in four of its six regions indicated that up to a third of immunization injections were not sterile. Immunization injections account for less than 10% of injections administered within the health sector. The United Nations estimates that more than half of all non-immunization injections in developing countries are unsafe. According to WHO, an estimated 40.0 million adults and children worldwide are infected with HIV, 90% of who live in developing countries.

Intravenous drug users, who share syringes or use syringes discarded by hospitals, medical clinics and laboratories, doctors or diabetic patients, are extremely susceptible to HIV, hepatitis and other blood-borne pathogens. An article in the May 1996 American Journal of Public Health for Disease Control written by an epidemiologist for the Center for Disease Control and Prevention (the "CDC") estimates that nearly half of all new HIV infections are occurring in intravenous drug users. In the United States, up to 30% of pregnant mothers infected with HIV transmit the virus to their babies, according to the CDC. Based on a study of children with HIV, who received care at Children's Hospital of Wisconsin, researchers estimated that the mean total lifetime costs of caring for a child with HIV was close to $1 million.

As a result of findings in the United States and developing countries, public health officials have encouraged the medical industry to develop safer syringes to prevent the spread of blood-borne pathogens, such as HIV and hepatitis. In 1995, the House of Delegates -- American Medical Association requested "manufacturers of disposable hypodermic needles and syringes to adopt designs to prevent reuse and to include in the packaging clear directions for their correct disposal." In late 1995, UNICEF and WHO recommended "the use of auto-disable syringes instead of disposable, single use syringes in order to avoid the hazards of unsafe injection practices."

-3-






Needlestick Prevention

Needlestick prevention devices are designed to prevent accidental puncture injuries to health care workers and patients before, during, and after the use of hypodermic syringes and needles. Statistics indicate that less than 1% of all reported HIV infections in the United States are attributed to needlestick injuries. The most prevalent needle stick prevention device, the extendible barrel sleeve, is not a substitute for features that render a syringe difficult-to-reuse; however, it can be combined with devices that make a syringe difficult-to-reuse. Needlestick prevention methods include:

Retracting Needles retract the needle into the barrel after use. These devices are effective needlestick prevention devices; however, operators must manually trigger the retraction of needles. Retracting needle devices that automatically trigger with a single use of the syringe can render the syringe design difficult to reuse. However, such devices are costly to manufacture due to the complexity of the mechanics required to retract the needle.


Self-Destruct Needles permit the needle to be collapsed or deformed into a shape, which cannot result in a needlestick injury. Although self-destruct needle devices are mechanically simpler than retracting needle devices, less prone to malfunction and less costly to manufacture, such devices are effective only if the operator triggers the self-destruct feature.

Extendible Barrel Sleeves enclose the barrel of the syringe in a second cylinder. The operator extends the sleeve before and after use to cover the tip of the needle. The extendible barrel sleeves often lock in the extended position after use. In virtually all designs, the operator of the syringe must manually extend the barrel sleeve after use. The sleeve does not prevent multiple use of the syringe before the operator encloses the barrel. However, extendible barrel sleeves are more cost-effective than the other alternatives and can be combined with a device that makes the syringe difficult to reuse.
 
UNIVEC Syringes

Univec has developed a 1cc AD-Syringe for aspirating and non-aspirating applications, which are ideally suited for dispensing accurate dosages of allergy, immunization and insulin medicines. The Company's 1cc AD-Syringe can deliver dosages of up to .95cc. With the aspirating syringe, the UNIVEC locking clip does not limit the user's ability to withdraw and depress ("to aspirate") the plunger until the user locks the syringe voluntarily. With the non-aspirating syringe, the UNIVEC locking clip limits the user's ability to aspirate the plunger and locks the syringe passively.

When the non-aspirating syringes are assembled, the syringe clip is placed on the ratcheted plunger in the position needed to limit dosage as desired. When the operator depresses the plunger, the clip travels down the barrel by an equal distance. Withdrawal of the plunger by any amount embeds the prongs into the barrel and the user cannot retract the plunger.

Univec's 1cc non-aspirating syringe was developed for the needs of immunization programs. Using existing components, the Company can limit its non-aspirating syringe to any dosage between .05cc and .95cc.

-4-






Univec's 1cc aspirating syringe works similarly to the non-aspirating model, except that the clip prongs do not engage the barrel until the operator withdraws the plunger completely. Once the operator does so, the clip catches a single ratchet and travels down the barrel as the plunger is depressed and the operator cannot withdraw the plunger.

Univec's 1cc aspirating syringe was developed for healthcare workers, who need to mix medications in the syringe barrel and inject medicines intravenously. Furthermore, the Company believes that aspirating syringes are preferred by diabetes patients and needle-exchange programs. The Company does not know of any other company that offers an aspirating syringe that can be locked.

Univec has licensed rights to a United States patent for a sliding sheath to function on all standard syringes. The Company believes that its licensed design for a safety syringe will compete successfully with the other safety syringes on the market. This design can be used on barrels of various sizes.

Marketing of Pharmaceutical Company Drug Samples to Physicians

PPSI patient StarterScript prescription drug program allows the physician to provide to the patient a cost effective means to support medication management from both a clinical and economic perspective. The patient sees if they may tolerate the medication under both the physician and pharmacist oversight.

The PPSI online network provides better marketing and clinical integration information than traditional systems, and enables pharmaceutical companies to maintain market share when competing with generic drugs. The PPSI information system includes detailed information such as the individual sales representative, zip codes, DEA number, pharmacy and prescribing physician. The PPSI system provides pharmaceutical companies with an easy, safe way to offer free samples through physicians and increase their value to patients who benefit through savings on prescriptions. In addition, the PPSI system provides incentives for chain drug stores to stock the pharmaceutical products and for pharmaceutical companies to keep their products on managed care formularies. Pharmaceutical manufacturers spend over $16 billion a year for the marketing of products. PPSI's strategy is to provide flexible sample programs supported by technology to assist with distribution, dispensing, reporting, and clinical integration that maximizes the intent of appropriate sample model for marketing.

Sales, Marketing and Distribution

Univec has entered into several agreements with large United States based wholesalers for the support and expansion of distribution channels for nationwide delivery of the Univec product line.

Univec also markets its StarterScript patient prescription sampling services to pharmaceutical companies desiring to maintain or expand market position. The company management believes that with the growth of third party payments of prescription drug such as Medicare and managed care companies the direct to consumer programs will grow. Univec also believes that with more branded pharmaceutical products coming off patent will further enhance direct patient sampling or StarterScript programs as an offense to generic drug substitution.

-5-







Univec has shipped its lcc AD-Syringes to over 80 countries. Univec intends to market its Safety-Shield syringes, as well as the Demolizer medical waste disposal system to governments of developing countries, private hospitals and health facilities in the United States, and distributors in the United States. Univec is a licensee of products and proprietary manufacturing processes relating to 1cc AD-Syringes. For manufacturing in our facilities. The Company markets such syringes to governments of developing countries, private hospitals and medical facilities. To stimulate demand for its safety syringes, Univec plans to initiate promotional and educational campaigns directed at (i) public health officers and other government officials responsible for public health policies, (ii) doctors and administrators of healthcare facilities responsible for treatment of HIV-AIDS and hepatitis patients, and (iii) liability insurance companies.

Univec also markets its drug sampling services to pharmaceutical companies desiring to maintain or expand market position.

Production

Univec's lcc locking syringes are being assembled by contract manufacturers in the United States and foreign countries. (See Item 1, "Description of Business" and Item 3 "Legal Proceedings" for the current status of the Company's business. The United States manufacturers also mold the Company's proprietary syringe plungers. Univec owns stamping, assembly, and molding equipment at its U.S. contract manufacturer. Univec relocated its clip plunger assembly production facility designed to produce 1cc AD-Syringes from Farmingdale, New York to Baltimore, Maryland during July 2003. These assemblies are shipped to our contract manufacturers to produce Auto-Disable Syringes.

Univec's syringes consist of a standard needle, barrel, rubber stopper, a ratcheted plunger designed by the Company, and a pronged stainless steel locking clip designed by Univec. The locking clip and plunger can be assembled, with minor modifications, into barrels manufactured by Becton-Dickinson, Tyco, and other syringe manufacturers. Univec has obtained a patent on its stainless steel locking clip, and has been granted a patent for the design of a plunger which, when combined with the locking clip, results in a narrow-barreled, difficult-to-reuse, locking syringe. The stainless steel for the locking clip and the plastic for the syringe barrels and plungers is readily available from several sources. The syringe barrels for some of the syringes sold by Univec have been manufactured by a Portuguese contract manufacturer. Univec has been successful through other sources worldwide in purchasing barrels to increase the overall production capacity. In addition, Univec continues to send clip plunger assemblies produced in the U.S. to syringe manufacturers to also increase overall production. Univec continues to pursue alternate sources of supply for components. Should there be a need for a certain component from an alternate supplier, there can be no assurance that the Company will be able to obtain it on acceptable terms, and there can be no assurance that production of certain configurations of its lcc locking syringes will not be delayed. Delays resulting from the selection of an alternate supplier to produce certain components could have a materially adverse effect on Univec's business.

-6-







Competition

Univec's principal competition for syringes is from traditional disposable syringes. Becton-Dickinson, Tyco and Terumo control approximately 90% of the worldwide syringe market, and are substantially larger, more established and have significantly greater financial, sales and marketing, distribution, engineering, research and development and other resources than the Company. To Univec's knowledge, only Becton-Dickinson and Bader, a German machine tool manufacturer, distribute commercially a line of difficult-to-reuse syringes, none of which allow for aspiration. The Bader DestroJect syringe and the Becton-Dickinson SOLOSHOT syringe were designed to dispense a dosage of .5cc only, whereas the UNIVEC 1cc locking clip syringe was designed to dispense dosages up to .95cc. Univec believes that UNIVEC syringes are more effective than competitors' difficult-to-reuse syringes and that the UNIVEC syringes are competitively priced. There can be no assurance that the major syringe manufacturers or others will not commence production of 1cc difficult to-reuse-syringes, or locking syringes which aspirate, or that Univec will be able to successfully compete in this market.

PPSI's competition comes from traditional sampling providers that include the actual drug samples and other pharmaceutical benefit management companies that offer similar services such as Caremark and Medco Health.

Patents, Licenses and Proprietary Rights

In 1995, Univec was granted a United States patent for a locking clip device not biased against the plunger. The patent is broad enough to include several applications of the design covering the first series of products to be marketed by Univec. Univec was granted a United States patent for a plunger design which, in conjunction with its patented locking clip, results in a narrow barrel, difficult-to-reuse syringe that allows for aspiration during use.

-7-






In the past, Univec has filed patent applications for its locking clip and aspirating plunger in certain foreign countries participating in the Patent Cooperation Treaty (Canada, Brazil, Mexico, certain European countries, Japan, South Korea, China, Russia and Australia). However, patent applications filed in foreign countries and patents granted in such countries are subject to laws, rules and procedures that differ from those in the United States, and accordingly, patent protection in such countries may be different from patent protection provided by United States laws. In December 2003, to settle an outstanding note with Syrinter, Ltd. (Switzerland), the Company assigned certain patents for the 1cc auto-disabled syringe as in full payment of the note and interest thereon. The Company in turn received relief from restrictive patent payments and a perpetual license to exploit these patents provided manufacturing occurs in the United States. In addition, the Company will continue to receive 15% of future royalties being earned from the licensing of these items.

Univec has registered trademarks UNIVEC(R), and Rx Ultra(R), Rx Plus, The Univec Crest and the symbol representing no second use, (i.e., the number 2 crossed out inside of a circle), with the United States Patent and Trademark Office.

In March 2001, Univec exercised an option to acquire a license of a component for a period of the later of ten years or the expiration of the last patent relating to the component and its improvements, with the right to terminate the agreement if the Company fails to produce and ship at least ten million of this component within three years. Univec is committed to pay a royalty of $.001, per component sold, with an advance royalty fee of $15,000 previously paid. As of December 31, 2005, Univec has sold only an insignificant amount subject to royalties under this agreement.

In July 2000, Univec received FDA approval of the sliding sheath syringe and began to manufacture and market this product in 2001.

In August 2000, Univec entered into a licensing agreement providing for the non-exclusive, worldwide use of Univec patents for the manufacturing, use and marketing of its auto-disable syringes through the period any patents are still in effect, providing for royalties on sales and for the sale of equipment necessary to manufacture the product. In accordance with this agreement, Univec has earned royalties of $0 and $30,284 for the years ended December 31, 2005 and 2004, respectively.
 
In 2003 the Company assigned certain patents to a creditor in payment of an amount due and also assigned the future royalties under the auto-disable syringe licensing agreement. The Company has licensed back the rights under these patents to market and manufacture in North America.

In 2004 the Company applied for and received a Provisional Patent from the U.S. Patent and Trademark Office on September 21, 2004, the Patent #60/611,670 and Foreign Filing License Granted October 15, 2004, code US60/611,670. However, patent applications filed in foreign countries and patents granted in such countries are subject to laws, rules and procedures that differ from those in the United States, and accordingly, patent protection in such countries may be different from patent protection provided by United States laws. In brief description, a medical device with a sliding sheath to protect caregivers in the dental and the cosmetic market.
 
-8-






Revenue Recognition

As a result of the differing circumstances related to the Company’s manufacture, procurement, distribution and physician sampling programs diverse financial accounting methods are utilized to recognize revenue from its various revenue sources. The Company’s manufacturing and specialty pharmaceutical drug distribution programs employ the “gross” method of recognizing revenue. However, because of the distinctive type of services provided to customers, the GPO and physician sampling programs utilize the “net” method of revenue recognition.

Government Regulation

The manufacture and distribution of medical devices are subject to extensive regulation by the FDA in the United States, and in some instances, by foreign and state regulatory authorities. Pursuant to the Federal Food, Drug, and Cosmetic Act, as amended, and the regulations promulgated there under (collectively, the "FDC Act"), the FDA regulates the clinical testing, manufacture, labeling, sale, distribution and promotion of medical devices. Before a new device can be introduced into the market, a manufacturer must obtain FDA permission to market through either the 510(k) pre-market notification process or the costlier, lengthier and less certain pre-market approval ("PMA") application process. With the 510(k) notification, the Company may sell its 1cc locking clip syringe in the United States, subject to compliance with other applicable FDA regulatory requirements. As a Class II device, performance standards may be developed for the 1cc locking clip syringe which the product would then be required to meet. Failure to meet standards for effectiveness and safety could require the Company to discontinue the manufacturing and/or marketing of the product in the United States. Furthermore manufacturers of medical devices are subject to record-keeping requirements and required to report adverse experiences relating to the use of the device. Device manufacturers are also required to register their establishments and list their devices with the FDA and with certain state agencies and are subject to periodic inspections by the FDA and certain state agencies.

Medical devices are subject to strict federal regulations regarding the quality of manufacturing ("Good Manufacturing Practices" or "GMP"). GMP regulations impose certain procedural and documentation requirements upon the Company with respect to manufacturing and quality assurance activities. The FDA conducts periodic audits and surveillance of the manufacturing, sterilizing and packaging facilities of medical device manufacturers to determine compliance with GMP requirements. These procedures may include a product recall or a "cease distribution" order which would require the manufacturer to direct its distributors and sales agents to stop selling products, as well as other enforcement sanctions. Univec's manufacturing facilities have not been certified as satisfying GMP requirements. Univec's facilities will be subject to extensive audits in the future, pursuant to standard FDA procedure. No assurance can be given that when the Company is audited that it will be found to be in compliance with GMP requirements, or that if it is not found in compliance, what penalties, enforcement procedures or compliance effort will be levied on or required of the Company. To date, Univec has not been audited by the FDA. The FDA also has the authority to request repair, replacement or refund of the cost of any device manufactured or distributed by the Company, and the failure to meet standards for safety and effectiveness could require the Company to discontinue marketing and/or manufacturing its product in the United States.


-9-






The introduction of Univec's products in foreign markets will also subject Univec to foreign regulatory clearances which may impose additional substantive costs and burdens. International sales of medical devices are subject to the regulatory requirements of each country. The regulatory review process varies from country to country. Many countries also impose product standards, packaging requirements, labeling requirements and import restrictions on devices. In addition, each country has its own tariff regulations, duties and tax requirements. Univec's products are required to satisfy international manufacturing standards for sale in certain foreign countries.

The approval by the FDA and foreign government authorities is unpredictable and uncertain, and no assurance can be given that the necessary approvals or clearances for the Company's products will be granted on a timely basis or at all. Delays in receipt of, or a failure to receive, such approvals or clearances, or the loss of any previously received approvals or clearances, could have a materially adverse effect on the business, financial condition and results of operations of the Company. Furthermore, approvals that have been or may be granted are subject to continual review, and later discovery of previously unknown problems may result in product labeling restrictions or withdrawal of the product from the market. Moreover, changes in existing requirements or adoption of new requirements or policies could adversely affect the ability of Univec to comply with regulatory requirements. There can be no assurance that Univec will not be required to incur significant costs to comply with applicable laws and regulations in the future. Failure to comply with applicable laws or regulatory requirements could have a materially adverse effect on Univec's business, financial position and results of operations.

Research and Development

For the years ended December 31, 2005 and 2004, Univec expended $3,802 and $28,871, respectively, on product development expenses.

Employees

As of December 31, 2005, Univec employed four persons, including two full time in sales and marketing, one full time in financial administration, and one full time in production. None of Univec's employees is covered by a collective bargaining agreement.

As of December 31, 2005, PPSI had no employees, but utilizes outside marketing representatives and consultants for marketing and employees of affiliated companies, owned by a stockholder/officer of the Company, to provide certain administrative services. These expenses, together with other expenses, have not been allocated between these companies.
 
Item 2. Description of Property.

Univec occupied a production facility, warehouse, administrative, and executive offices in Baltimore, MD (comprised of approximately 22,000 square feet of space) pursuant to a lease that expired on July 15, 2004 with ten (10) renewable one (1) year option terms which are automatically renewable by Univec. Rental expense for the space is $72,000 per annum plus certain common charges, maintenance costs and real estate taxes, subject to a maximum increase of 3% for each three year term. The lease on this facility was terminated on February 6, 2006.

-10-







Item 3. Legal Proceedings.

In February 2000, a former consultant commenced an action against the Company and its directors, Alleging breach of contract and fiduciary duty, and is seeking consulting fees in the amount of: (1) 250,000 shares of common stock, (2) $192,000 and (3) costs of this action. The Company and counsel do not believe the consulting fees are due and will continue to vigorously defend this action.
 
Item 4. Submission of Matters to Vote of Security Holders
 
The Annual Meeting of Stockholders of Univec, Inc. for the year ended December 31, 2004, was held on October 14, 2005, to consider and vote upon a proposal to elect S. Robert Grass, Dr. David Dalton and William Wooldridge as directors.

A second proposal was presented and voted upon to amend the Articles of Incorporation to effect a one-for-ten reverse stock split of the issued and outstanding shares of common stock and correspondingly to decrease the share capital from 75,000.000 shares to 7,500,000 shares, then to increase the share capital from 7,500,000 shares to 50,000,000 shares on a date to be determined by the Board of Directors.

A third proposal was considered and voted upon to give authorization to the Board of Directors to change the name of the corporation to another or new name on a date to be determined by the Board of Directors.
 
The number of votes cast for and the number of abstentions are set forth below:

Proposal 1 -  Election of Directors
 
 
  
For
  
Withhold
S. Robert Grass
  
35,227,022
  
0
David Dalton
  
35,227,022
  
0
William Wooldridge
  
35,227,022
  
0
 
Proposal 2 -  To amend the Articles of Incorporation to effect a one-for-ten reverse stock split of the issued and outstanding shares of common stock and correspondingly to decrease the share capital from 75,000.000 shares to 7,500,000 shares, then to increase the share capital from 7,500,000 shares to 50,000,000 shares on a date to be determined by the Board of Directors.
 
 
  
For
  
Withhold
Total vote result for Proposal 2
  
35,227,022
  
0

Proposal 3 -  To give authorization to the Board of Directors to change the name of the corporation to another or new name on a date determined by the Board of Directors.
 
 
  
For
  
Withhold
Total vote result for Proposal 3
  
35,227,022
  
0
 
-11-






Item 5. Market for Common Equity and Related Stockholder Matters.

(a)(1) Prior to July 2, 1999, the Company's Common Stock and redeemable Common Stock Purchase Warrants (expired April 2002) traded on the Nasdaq Small Cap Market. Following that date, the common stock and warrants have been quoted on the OTC Bulletin Board under the symbols "UNVC" and "UNVCW", respectively.

Set forth below are the high and low closing sale prices for the Common Stock on the over-the-counter bulletin board from January 1, 2004 through December 31, 2005 and the first quarter of 2006.

 
Common Stock
 
("UNVC")
Quarter Ended
High
Low
 
 
 
March 31, 2004
$ 0.150
$ 0.090
June 30, 2004
$ 0.120
$ 0.070
September 30, 2004
$ 0.090
$ 0.060
December 31, 2004
$ 0.110
$ 0.040
March 31, 2005
$ 0.120
$ 0.080
June 30, 2005
$ 0.110
$ 0.030
September 30, 2005
$ 0.050
$ 0.020
December 31, 2005
$ 0.040
$ 0.020
March 31, 2006
$ 0.020
$ 0.020


(1) As of December 31, 2005, there were 120 holders of record of the Common Stock.

(2) During the fiscal year ended December 31, 2005, Univec sold unregistered securities to a limited number of persons in transactions exempt from the registration requirements of the Securities Act, as described below. Except as indicated, there were no underwriters involved in the transactions, and there were no underwriting discounts or commissions paid in connection therewith. The purchasers of securities in each such transaction represented their intention to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof and appropriate legends were affixed to the certificates for the securities issued in such transactions. All purchasers of securities in each such transaction had adequate access to information about Univec, and in the case of transactions exempt from registration under Section 4(2) of the Securities Act, were sophisticated investors.
 
1. On January 10, 2005, the Company issued 698,893 shares of common stock to officers of the Company in exchange for payroll earned of $35,364. During March 2005, another 250,000 common shares were issued to an officer in exchange for payroll earned of $20,400.
 
2. On January 10, 2005, the Company issued 339,087 shares of common stock to an officer/director of the Company in exchange for benefits not taken of $17,158.

3. On January 20, 2005, the Company issued 804,688 common shares to a preferred stockholder in exchange for 30 shares of Series E preferred stock and unpaid dividends worth an aggregate of $32,188.


-12-






4. During March 2005, the Company sold 350,000 common shares to independent investors for $35,000.

5. On March 9, 2005, the Company sold 20,833 Series D Preferred shares for $50,000.

6. On April 6, 2005, the Company issued 1,386,527 common shares to a preferred stockholder in exchange for 70 shares of Series E preferred stock and unpaid dividends worth an aggregate of $5,843.

7. On June 28, 2005, the Company issued 1,896,970 shares of common stock to two
officers in exchange for operating expenses incurred by them but not previously paid.

8. On June 29, 2005, the Company issued 1,500,000 shares of common stock to an independent marketing consultant in exchange for fees not paid of $45,000.

9. On June 30, 2005, the Company issued 1,286,082 shares of common stock to an officer/director of the Company in exchange for benefits not taken of $42,441.
 
10. On June 30, 2005, the Company converted $70,000 of notes payable to an affiliated company owned by an executive officer in exchange for 2,333,333 shares of common stock.

11. On October 10, 2005, the Company issued 1,169,850 shares of common stock to an officer/director of the Company in exchange for benefits not taken of $12,868.
 
-13-




 
Item 6. Management's Discussion and Analysis
 
The following discussion and analysis should be read in conjunction with Univec, Inc's ("Univec", "we" or "our"), consolidated financial statements, including the notes thereto, appearing elsewhere in this report.

Condensed Consolidated Results of Operations

 
  
2005
  
2004
  
Change
  
 
                 
Revenues
  
$
81,398
  
$
327,827
    
(75
%)
 
                    
 
              

Cost of Revenues
   
(3,164
)
  
128,933
    
(102
%)
 
                    

Gross Margin
    
84,562
    
198,894
    
(57
%)
 
                    
Expenses:
                    
 
                    
Marketing and Selling
                    
   Expense
   
233,990
    
123,400
    
90
%
Product Development
    
3,802
    
28,871
    
(87
%)
General and
                    
   Administrative
   
1,535,840
    
1,772,246
    
(13
%)
Loss on write-off of
                    
   Goodwill
        
1,774,119
    
-
  
Interest Expense, Net
    
200,019
    
108,092
    
85
%
Gain on Extinguishment
                    
   of Debt
       
(144,819
)
  
-
  
Other Income
     -    
(47,795
)
  
-
  
 
                    
Total Expenses
   
1,973,651
    
3,614,114
    
(45
%)
 
                    
Discontinued Operations
        
(8,260
)
  
-
  
Loss on sale of Subsidiary
     -    
(597,056
)
  
-
  
 
                    
Net Loss
 
$
(1,889,089
)
$
(4,020,536
)
  
(53
)%
 
                    

 
-14-



Sales within PPSI’s GPO comprised 50% of the total sales for 2005. The GPO program utilizes the “net” method of revenue recognition.

A breakdown of revenues and cost of revenues for 2005 between the Company and its wholly-owned subsidiary, PPSI, are as follows:

 
  
Univec
  
PPSI
  
Total
  
Revenue 
  
$
40,793
  
$
40,605
  
$
81,398
  
Cost of Revenues 
    
3,164
     -    
3,164
  
 
              
Gross Margin
  
$
43,957
  
$
40,605
  
$
84,562
  
 
              
 
The Company has its focus on the marketing, production, development and distribution of its pharmaceutical and proprietary products and licensing of the technology of its insulin and tuberculin sliding sheath safety syringes.

Sales within PPSI’s GPO program utilizing the “net” revenue recognition comprised 48% and 82% of the total revenue for 2005 and 2004, respectively.

Gross profit for the year ended December 31, 2005 decreased to 0.4% from 1.0% in 2004. Gross profit based on product sales for 2005 decreased to $39,871 as compared to $198,894 in 2004. The reduced gross profit is primarily due to the lower sales revenue and lower gross profit contribution from PPSI’s GPO revenue and also from lower sales volume of our 1cc clip syringe. The GPO gross profit was 0.4% and 1.4% for the years 2005 and 2004, respectively. The reduction of syringe gross profit is largely the result of decreased sales volume. We anticipate gross profit levels to remain at current levels, unless we increase our market penetration, our prices, product mix and/or realize anticipated production or economic benefits that we anticipate as a result of our relocation to Maryland from New York during 2003 and our 2004 financings.

As a result of the acquisitions of PPSI, we have broadened our pharmaceutical product distribution base. We anticipate increases in sales on a period by period basis from PPSI if we can increase our market penetration in these areas. However, during 2005 our largest CPO customer was unable to renew a significant contract, which resulted in a significant loss of sales by PPSI.

Marketing and selling costs in 2005 increased $110,590 (90%) from 2004. This increase is attributable primarily to increases in compensation and consulting costs, which were as a result of our increased efforts to increase corporate revenues.

Product development expense for 2005 decreased by $25,069 (87%) as compared to 2004. This decrease was the result of reduced expenditures for product design and engineering costs, which were curtailed until financing became available to market a new medical syringe with a sliding sheath to protect caregivers in the dental and the cosmetic market.

General and administrative expenses for the year ended December 31, 2005 decreased $236,406 (13%) as compared to 2004. This decrease is due primarily to reductions in compensation, insurance, equipment costs and securities maintenance expenses offset in part by increases in professional fees and travel costs.

Interest expense for the year ended December 31, 2005 increased by $91,927 (85%) as compared to 2004 primarily as a result of increased debt outstanding during 2005.

-15-



During the year ended December 31, 2004, the Company determined that an extremely minimal net income had been generated by the wholly owned subsidiary which had been acquired utilizing $1,774,119 of goodwill. The Company also determined that future profitability of the subsidiary was also in doubt. This lack of profitable operations led to the conclusion that the goodwill had been completely impaired and therefore the entire goodwill balance was written-off. The subsidiary owns no physical assets.

Other income for the year ended December 31, 2004 included $36,349 gain on the sale of marketable securities plus $11,446 gain on the sale of equipment.

The Company had a net loss of $1,889,089 for the fiscal year ended December 31, 2005, as compared to a net loss of $4,020,536 for the year ended December 31, 2004. The decreased loss of $2,131,447, or 53%, during 2005 was attributable in part to the 2004 nonrecurring loss of $597,056 on the sale of a subsidiary. The subsidiary was sold during August 2004 in order to reduce the fixed costs associated with its operation. The Company incurred a 2004 nonrecurring $1,749,235 loss on the write-off of goodwill, the $597,056 loss on the sale of a subsidiary and an offsetting gain on extinguishment of debt of $144,819. This increased portion of the Company’s net loss was further related to the 2005 $131,332 reduction in gross profit.

The December 31, 2005 net loss included $787,447 payroll and related expenses versus $849,547 for the year ended December 31, 2004. Insurance expense was $153,969 during 2005 versus $210,696 during 2004. Product development expense was $3,802 during 2005 versus $28,871 during 2004. Professional fees for the year ended December 31, 2005 were $385,093 versus $335,875 incurred for the year ended December 31, 2004.

Liquidity and Capital Resources

The working capital deficit of $4,207,570 at December 31, 2004, increased to a deficit of $5,116,766 at December 31, 2005. This reduction of working capital is primarily attributable to the Company’s $1,933,780 net loss. However, net decreases in accounts receivable and increases in deferred compensation were partially offset by decreases in accounts payable and accrued expenses and also by a decrease in total loans payable. All of these factors contributed to the overall decrease in working capital.

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of December 31, 2005, the Company had negative working capital of $5,116,766 and a stockholders' deficit of $4,900,219 and incurred net losses of $(1,933,780) and $(4,020,536) for the years ended December 31, 2005 and 2004, respectively. These factors, among others, indicate that the Company's continuation as a going concern is dependent upon its ability to obtain adequate financing and/or achieve profitable operations. The financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

Management is currently seeking additional investment capital to support its entrance into new business ventures and provide the capital needed to operate.

Net cash used in operating activities decreased by $428,502 (57%) to $319,482 for the year ended December 31, 2005 from 2004, primarily due to the continued net loss.
 
Net cash provided by investing activities of $326,907 resulted from the redemption of restricted cash deposits, which was partially offset by the purchase of fixed assets during 2005.
 
Net cash used in financing activities increased by $1,544,628 (102%) to $(35,877) for 2005 from $1,508,751 provided during 2004. This increase in net cash used in financing activities resulted from a decrease in aggregate borrowings of $1,363,827 and an increase in aggregate repayments of borrowings of approximately $218,969. There was also an $85,000 non-recurring sale of securities during 2005.
 
-16-
 
 
Although revenue decreased as a result of the 2005 PPSI GPO operations for the year ended December 31, 2005, we continued to market our safety syringes. We suffered from a serious shortage of working capital, which resulted in the Company’s limited ability to market and sell its products.

In July 2004, the Company borrowed an aggregate of $1,000,000 from a city development agency, ,a state development agency and a stockholder. These proceeds provided us with resources to acquire equipment, refinance an equipment capital lease and for working capital to enable us to continue to implement our business strategy. The proceeds from the above loans and our designation as a minority business enterprise (MBE) should increase our marketing service capabilities to pharmaceutical companies and to develop new products.
 
Unless we introduce new products or increase our market share Univec’s management anticipates that operations will generate a negative cash-flow during our next fiscal year, but there can be no certainty this will occur.
 
The relatively low trading price and volume of our common shares hampers our ability to raise equity capital. There is no assurance that any such equity financing will be available to the Company or on terms we deem favorable. Management will continue its efforts to obtain debt and/or equity financing.
 
Significant Estimates

Univec's business plan upon acquiring PPSI was to fully utilize each other's capabilities to increase their sales and profitability. Although a shortage of cash flow has slowed the plan, management has reviewed the carrying amount of goodwill and fixed assets. We have considered all the circumstances, specifically the fair value based on current and anticipated future undiscounted cash flows. In addition, as part of our relocation strategy, various production equipment is being reevaluated. During 2004, the Company determined that the goodwill with a carrying value of $1,774,119 had been fully impaired and has written-off the entire balance.
 
New Accounting Pronouncements

Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements. Financial Accounting Standards Board Statement # 123R Stock Based Compensation is not expected to have a material effect on the Company’s financial statements.

Major Customer - Certain Relationships and Related Transactions

For the year ended December 31, 2005, our largest customer, Pharmacy Services, Inc., a company owned and operated by Dr. David Dalton, President and Chief Executive Officer, purchased goods and generated revenues of $40,605 from PPSI’s GPO. We intend to reduce our reliance on this customer through expanding sales to other parties.

Forward Looking Statements

Except for the historical information contained herein, the matters discussed in this report are forward-looking statements that involve risks and uncertainties, including market acceptance of Univec's products, timely development and acceptance of new products, impact of competitive products, development of an effective organization, interruptions to production, and other risks detailed from time to time in Univec's SEC reports and its Prospectus dated April 24, 1997 (as supplemented by the Prospectus Supplement dated April 29, 1997) forming a part of its Registration Statement on Form SB-2 (File No.333-20187), as amended, which was declared effective by the Commission on April 24, 1997.
 
-17-



Item 7. Financial Statements.

The financial statements follow Item 13 of this report.

Item 8. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

A Form 8-K was filed on June 13, 2005 and amended by two Forms 8-K/A filed on August 1, 2005 and January 11, 2006. These filings reported the resignation of the Company’s principal registered independent public accounting firm. Further, the Registrant reported that the auditor’s report for the previously issued Form 10-KSB for the year ended December 31, 2003 could no longer be relied upon. Also, the former principal registered independent public accounting firm has informed the Registrant that it may no longer rely upon review reports issued for all Form 10-QSB for all quarters starting with the quarter-ended March 31, 2003 through the quarter-ended September 30, 2004.

The Company did file a Form 10-KSB amendment on January 11, 2006. This report bore a qualification as to the Company’s ability to continue as a going concern.
 
 
Item 8A CONTROLS AND PROCEDURES
 
(a) Based on their evaluation required by Rule 13a-15(b) or 15d-15(b) under the Securities and Exchange Act of 1934 (the “Exchange Act”), management, including the Chief Executive Officer and Chief Financial Officer, concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were effective as of the end of the period covered by this report. Although the Company did change from the “gross” to the “net” revenue method of accounting for the GPO (Group Purchasing) and physician sampling programs use the “net” method of revenue recognition, this change to a more appropriate accounting method does not reflect on the effectiveness of the controls applied in the circumstances.
 
(b) Changes in internal controls. There were no significant changes in the Company's internal controls or in other factors that could significantly affect the Company's disclosure controls and procedures subsequent to the Evaluation Date, nor any significant deficiencies or material weaknesses in such disclosure controls and procedures requiring corrective actions. As a result, no corrective actions were taken.
 
-18-






Item III
 
Item 9. Directors, Executive Officers, Promoters and Control Persons; Compliance With Section 16(a) of the Exchange Act.
 
Directors, Executive Officers and Key Employees

The directors, executive officers and key employees of Univec are as
follows:

Name
Age
 Position  
Dr. David Dalton
57
Chief Executive Officer, President and a Director
S. Robert Grass
72
Chairman of the Board of Directors
William Wooldridge
60
Director
Raphael Langford
61
Chief Operating Officer and Executive Vice President
Michael Lesisko
56
Treasurer, Secretary and Chief Financial Officer


Dr. David Dalton assumed the position of President and Chief Executive Officer of the Company on January 1, 2002, concurrent with the acquisition by Univec, Inc. of Physician and Pharmaceutical Services, Inc. (PPSI), a Baltimore based company founded by Dr. Dalton. Dr. Dalton has over 35 years experience in the healthcare industry, including 18 years with Rite-Aid where he served as Corporate Vice President.

Dr. Dalton founded Health Resources, Inc., in 1983, a pharmacy service provider having contracts with over 50,000 retail pharmacies for billing and payment of prescription orders through plan providers. HRI is recognized as one of the leading Black Enterprises in the United States. Dr. Dalton also founded Pharmacy Services, Inc., a pharmacy fulfillment center for correctional and other institutions, with facilities in Maryland, Tennessee and Pennsylvania.

On March 15, 2002 S. Robert Grass was elected a director of Univec. He was elected Chairman of the Board of Directors in May, 2002. Mr. Grass has been associated with the pharmaceutical and medical device industry for over thirty-two years. Mr. Grass developed a chain of pharmacies known as White Shield Drugstores in Pennsylvania, serving as President, Chief Executive Officer and Chairman of the Board from 1970 to 1996. Mr. Grass also served as Chief Executive Officer and Chairman of the Board of Managed Care RX, a drug fulfillment and mail order business from 1994 to 1999.
 
 
-19-




 
William Wooldridge has been a director since August 5, 2003. Mr. Wooldridge is a recognized and respected entrepreneur. He is the founder of MedEcon, Inc. one of the largest group purchasing organizations in the United States. Over a twenty-eight year period he has developed a corporation with medical portfolio sales in excess of $3.5 billion. In 1999, Mr. Wooldridge formed OrderButton.Net, a new web-based transaction processing service that facilitates the establishment of merchant sites on the internet. Since 2002, Mr. Wooldridge has been developing a franchised, non-traditional based photography company.
 
Raphael Langford has been Chief Operating Officer of the Company since April 2003. Prior to April 2003, Mr. Langford was the Executive Director of the National Foundation of Women Legislators. Mr. Langford served as liaison to Federal and State elected officials. Mr. Langford has over thirty-five years experience in senior management positions with AT&T, Inc., Norton Simon, Inc. and other telecommunications entities. Mr. Langford is a past president and past Chief Executive Officer of Olympic International, Inc. This company is an international broker and manufacturing network of raw materials to third world countries.

Michael Lesisko, a certified public accountant, was named as Chief Financial Officer of Univec on September 9, 2002. Mr. Lesisko was named Treasurer and Secretary of Univec on February 11, 2003. From June 1996 to September 2002 Mr. Lesisko was a CPA in public practice. He served as Vice President of Finance of CarrerCom Corporation and Subsidiaries from November 1988 to May 1996. Prior thereto, he served as a partner with KPMG Peat Marwick from July 1982 to August 1988, where he managed financial audits and a diverse tax practice.

All directors hold office until the annual meeting of stockholders of the Company following their election or until their successors are duly elected and qualified. Officers are appointed by the Board of Directors and serve at its discretion.

Meetings of the Board of Directors and Information Regarding Committees

The Board of Directors has two standing committees, an Audit Committee and a Compensation Committee. On June 21, 2005, William Wooldridge was elected to the Audit Committee. The duties of the Audit Committee include recommending the engagement of independent auditors, reviewing and considering actions of management in matters relating to audit functions, reviewing with independent auditors the scope and results of its audit engagement, reviewing reports from various regulatory authorities, reviewing the system of internal controls and procedures of Univec, and reviewing the effectiveness of procedures intended to prevent violations of law and regulations. TheAudit Committee held two meetings in 2005. On October 14, 2005, Mr. S. Robert Grass was elected to the Compensation Committee. There was one meeting of the Compensation Committee in 2005.

The Board of Directors held seven meetings in 2005, which included special telephonic meetings. All Directors attended at least 75% of the total number of Board meetings and meetings of committees on which they served during the period they served thereon during 2005.


20-





Section 16(a) Beneficial Ownership Reporting

Section 16(a) of the Securities Exchange Act of 1934 requires Univec's Officers, Directors and persons who own more than ten percent of a registered class of Univec's equity securities within specified time periods to file certain reports of ownership and changes in ownership with the Securities and Exchange Commission (the "Commission"). Officers, Directors and ten percent stockholders are required by regulation to furnish Univec with copies of all Section 16(a) forms they file. Based solely on a review of copies of such reports received by Univec and written representations from such persons concerning the necessity to file such reports, Univec is not aware of any failures to file reports or report transactions in a timely manner during the fiscal year ended December 31, 2005.
 

Item 10. Executive Compensation.

The following table sets forth the compensation awarded to, earned by or paid to Univec's Chief Executive Officer and each other executive officers of the Company whose salary and bonus for the two years ended December 31, 2005 exceeded $100,000.
 
 
  
 
  
Annual Compensation
  
Long-Term Compensation
  
 
  
 
  
 
  
Other Annual
  
Securities
  
Name and Principal Position
  
Year
  
Salary
  
Compensation
  
Underlying Options
  
 
                      
Dr. David Dalton
    
2004
  
$
396,000(1
)
  
-
    
0 (1
)
Chief Executive Officer and
                          
President
                          
 
    
2005
  
$
435,600(2
)
  
-
    
0 (2
)

(1) ) During 2004, Dr. David Dalton earned a salary of $396,000, plus life, health and disability insurance, as well as an automobile lease and insurance allowance equal to $24,000 per year.

(2) During 2005, Dr. David Dalton earned a salary of $435,600, plus life, health and disability insurance, as well as an automobile lease and insurance allowance equal to $24,000 per year.
 
21-





Employment Agreements

Dr. David Dalton provides the amount of time necessary to perform his corporate duties. Dr Dalton's salary was $435,600 for 2005, plus a bonus determined by the agreement of Dr. Dalton and the Compensation Committee. On each January 1, the base salary will be increased by an amount agreed upon by Dr. Dalton and the Compensation Committee. The agreement also provides Dr. Dalton with an option to purchase 2,000,000 shares of Common Stock at an exercise price of $.24 per share, vesting 500,000 shares on the first anniversary of the agreement, and an additional 41,667 shares vesting each month following the initial vesting date. The unexpired term of the agreement will be extended automatically by one year on each January 1 following the date of the agreement, such that the unexpired term of the agreement will at all times not be less than two years following each extension. The agreement provides for payment by Univec of annual premiums on a term life insurance policy with a face amount of $2 million. The agreement also provides for health and disability benefits, as well as an automobile lease and insurance allowance equal to $24,000 per year. Under the terms of the agreement, Dr. Dalton is entitled to a severance payment equal to his highest annual base salary during the term for the remainder of the term if the agreement is terminated by Dr. Dalton for good reason, or in the event of a change in control of Univec.

Stock Options

The following table contains information concerning the grant of stock options to Dr. David Dalton ( the "Named Executive Officer") during the fiscal year ended December 31, 2005.

 
Number of Shares
Percent of Total Options
 
 
 
Underlying Options
Granted to Employees in
Exercise Price
Expiration
Name
Granted
Fiscal Year
Per Share
Date
Dr. David Dalton
-
0%
$0.00
N/A

 
AGGREGATED OPTION/SAR EXERCISES IN LAST FISCAL YEAR AND FISCAL YEAR END OPTION/SAR VALUES

The following table summarizes for Dr. Dalton the total number of shares acquired upon exercise of options during the year ended December 31, 2005, and the value realized (fair market value at the time of exercise less exercise price), the total number of unexercised options, if any, held at December 31, 2005, and the aggregate dollar value of in-the-money, unexercised options, held at December 31, 2005. The value of the unexercised, in-the-money options at December 31, 2005, is the difference between their exercise or base price, and the fair market value of the underlying Common Stock on December 31, 2005. The closing bid price of the Common Stock on December 31, 2005 was $0.02.
 
 
Shares Acquired Upon
Number of Securities
In-The-Money
 
Exercise of Options
Underlying Unexercised
Options at
 
During Fiscal 2005
Options at December 31, 2005
December 31, 2005
Name
Number
Value Realized
Exercisable
Unexercisable
Exercisable
Unexercisable
 
 
 
 
 
 
 
Dr. David Dalton
None
None
3,083,342
416,658
$ -
$ -

-22




Certain Transactions

At December 31, 2005, the following Deferred Payroll was payable to executive officers and other employees:
 
David Dalton, Chief Executive Officer and President
 
$
1.291,600
 
Raphael Langford, Chief Operating Officer
 
 
205,169
 
Michael Lesisko, Secretary - Treasurer
 
 
181,442
 
 
 
 
1,678,211
 
Other employees
 
 
200,272
 
 
 
$
1,878,483
 
 
At December 31, 2005, notes payable to companies owned by David Dalton, President, amounted to $815,510. These loans are the result of providing working capital to the Company.

At December 31, 2005, notes payable to David Dalton, President amounted to $100,000 and notes payable to S. Robert Grass, Chairman of the Board of Directors amounted to $208,300. These amounts were advanced to the Company at terms and rates similar to commercial bank provisions. The funds were provided to the Company for working capital operating needs.

On January 20, 2005, the Series E preferred stockholder exchanged 30 preferred shares plus $2,187 accrued dividends for 804,688 shares of Common Stock at $0.040 per share On April 6, 2005 this Series E preferred stockholder exchanged 70 preferred shares plus $5,843 accrued dividends for 1,386,527 shares of Common Stock at $0.0547 per share

On January 7, 2005, two executive officers exchanged a combined $52,879 of accrued payroll for 698,893 common shares at $0.075 per share. On March 13, 2006 an executive officer exchanged $29,892 of accrued payroll for 250,000 common shares at $0.120 per share These exchanges were authorized by the Company's Board of Directors on August 5, 2003.

On June 30, 2005, the Company's Chief Executive Officer exchanged $42,441 of employment Contract benefits for 1,286,082 common shares. On October 12, 2004, the Chief Executive Officer exchanged an additional $12,868 of employment contract benefits for 1,169,850 common shares. These exchanges were authorized by the Company's Board of Directors on August 5, 2003

 
-23-




 
Item 11. Security Ownership of Certain Beneficial Owners and Management

The following table sets forth certain information concerning the beneficial ownership of the Common Stock as of December 31, 2005 by (i) each stockholder known by the Company to be a beneficial owner of more than five percent of the outstanding Common Stock, (ii) each director of the Company and each Named Executive Officer and (iii) all directors and officers as a group.

 
Amount and Nature of Beneficial
Percentage of common Stock Beneficially
Name
Ownership (1)
Owned (2)
 
 
 
David Dalton (4)
24,816,320 (5)
40.82% (6)
S. Robert Grass (4)
1,065,951 (9)
1.83% (10)
William Wooldridge (4)
250,000 (13)
0.43% (14)
Raphael Langford (4)
3,366,667 (7)
5.73% (8)
Michael Lesisko (4)
2,640,668 (11)
4.49% (12)
All directors and executive
 
 
officers as a group (5 persons)
32,139,606 (3)(16)
50.29% (17)
 
 
 
Emerald Capital Partners LP
6,000,000
10.41% (15)

(1) Unless otherwise indicated, each person has sole investment and voting power with respect to the shares indicated, subject to community property laws, where applicable. For purposes of computing the percentage of outstanding shares held by each person or group of persons named above as of December 31, 2005 any security which such person or group of persons has the right to acquire within 60 days after such date is deemed to be outstanding for the purpose of computing the percentage ownership for such person or persons, but is not deemed to be outstanding for the purpose of computing the percentage ownership of any other person.

(2) Except as otherwise stated, calculated on the basis of 57,634,282 shares of Common Stock issued and outstanding on December 31, 2005.

(3) For purposes of this calculation, shares of Common Stock beneficially owned by more than one person have only been included once.

(4) Address is c/o the Company, 10 E. Baltimore Street, Suite 1404, Baltimore,  Maryland 21202.

(5) Includes 3,166,676 shares issuable upon exercise of presently exercisable options.

(6) Calculated on the basis of 60,800,958 shares of Common Stock issued and outstanding.
 
(7) Includes 1,133,333 shares issuable upon exercise of presently exercisable options.

-24-






(8) Calculated on the basis of 58,767,615 shares of Common Stock issued and outstanding.

(9) Includes 312,501 shares issuable upon conversion of Series D Preferred Stock and 250,000 issuable upon exercise of presently exercisable options.

(10) Calculated on the basis of 58,196,783 shares of Common Stock issued and outstanding.

(11) Includes 1,166,667 shares issuable upon exercise of presently exercisable options.

(12) Calculated on the basis of 58,800,949 shares of Common Stock issued and outstanding.

(13) Includes 250,000 shares issuable upon exercise of presently exercisable options.

(14) Calculated on the basis of 57,884,282 shares of Common Stock issued and outstanding.

(15) Calculated on the basis of 57,634,282 shares of Common Stock issued and outstanding.
 
(16) Includes 6,279,177 shares issuable upon exercise of presently exercisable options.

(17) Calculated on the basis of 57,634,282 shares of Common Stock issued and outstanding.

Item 12. Certain Relationships and Related Transactions

During 2003, Univec received a line of credit from Dr. David Dalton, President and Chief Executive Officer, and S. Robert Grass, Chairman of the Board of prime plus 2%, per annum. This line of credit was issued under the same terms as an underlying line of credit which Dr, Dalton and Mr. Grass received from a commercial bank. As of December 31, 2005, the outstanding balance of this loan was $200,000.

During February 2004, Univec borrowed $50,000 from Mr. S. Robert Grass, Chairman of the Board of Directors, repayable on demand at prime plus 2%, per annum.

During the years ended December 31, 2005 and 2004, Univec has borrowed an aggregate of $873,904 from Pharmacy Services, Inc., Health Resources, Inc. and other companies all owned by Dr. David Dalton, President and Chief Executive Officer. These loans are repayable on demand at 10%, per annum. At December 31,2005 and 2004, the aggregate balance outstanding was $815,510 and $578,800, respectively.


-25-







During 2005, Pharmacy Services, Inc., a company owned by Dr. David Dalton, President and Chief Executive Officer, purchased $9,936,042 from PPSI's GPO. This transaction represented 99% of total revenue.

PPSI shares office space and other administrative expenses with affiliated companies owned by Dr. David Dalton, the Chief Executive Officer of Univec. These expenses have not been allocated between the companies, but PPSI's portion would be insignificant.

Item l3. Exhibits and Reports on Form 8-K.

A Form 8-K was filed on July 31, 2006, reporting the completion of a private placement of a $2,000,000 6% Note and Warrants Securities Purchase Agreement. The agreement allows the investor to purchase 10,000,000 common stock warrants for seven years at an exercise price of $0.02 each. The Note and Warrants were issued in reliance upon exemptions from registration pursuant to Section 4(2) of the Securities Act of 1933 and Rule 506 of Regulation D promulgated thereto. Each of the Investors is an accredited investor as defined in Rule 501 of Regulation D under the Securities Act of 1933.

(a) Exhibits

Exhibit
Description
   
2.1(1)
Stock Purchase Agreement and Plan of Reorganization made and entered into as of December 31, 2001, by and among Physician and Pharmaceutical Services, Inc. ("PPSI"), the stockholder of PPSI and the Registrant.
   
2.2(2)
Stock Purchase Agreement made and entered into as of February 28, 2002, by and among Thermal Waste Technologies, Inc. ("TWT"), the stockholders of TWT and the Registrant.
   
3.1(4)
Restated Certificate of Incorporation of the Registrant, as amended.
   
3.2(3)
By-laws of the Registrant, as amended. 4.1(3) Agreement and Plan of Merger dated as of October 7, 1996 between the Registrant and UNIVEC, Inc., a New York corporation.
 
 
4.3(3)
Form of warrant between the Registrant and the underwriters of the Registrant's initial public offering.
   
4.4(3)
Specimen Common Stock Certificate.
   
4.5(3)
Specimen Warrant Certificate (included as Exhibit A to Exhibit 4.3 herein).
   

 
-26-






4.6(3)
Registration Rights Agreement among Registrant and the holders of bridge warrants.
   
4.7(5)
Certificate of Designation of Series B Preferred Stock. 4.8(6) Certificate of Amendment of Certificate of Designation of Series B Preferred Stock.
   
4.9(5)
Form of Warrant Agreement dated July 27, 1998, between Company and selling security-holder.
   
4.10(6)
Form of Amended and Restated Warrant Agreement, amending and restating the Warrant Agreement dated July 27, 1998, between the Company and the selling security-holder.
 
 
4.11(5)
Registration Rights Agreement dated July 27, 1998, between the Company' and selling security-holder.
   
4.12(6)
Registration Rights Agreement, dated February 8, 1999, between the Company and the selling security-holder.
   
4.13(6)
Certificate of Designation of Series C Preferred Stock. 4.14(6) Form of Warrant Agreement dated February 8, 1999. between the Company and selling security-holder.
   
10.1(3)
Amended 1996 Stock Option Plan of the Registrant.
   
10.2(7)
1998 Stock Option Plan of the Registrant.
   
10.3(8)
2000 Stock Option Plan of the Registrant.
   
10.4(7)
Employment Agreement dated as of September 4, 1998 between the Registrant and Joel Schoenfeld.
   
10.5(9)
Patent License Agreement dated August 16, 2000 by and between the Company and Terumo Europe, NV.
   
10.6(9)
Manufacturing Agreement dated August 16, 2000, by and between the
 
Company and Terumo, N.V.
   
10.7(9)
Equipment Purchase Agreement dated August 16, 2000, by and between the Company and Terumo Europe, N.V.
   
10.10(9)
Employment Agreement dated as of January 1, 2002, between the Registrant and David L. Dalton.
   
   
10.11
Employment Agreement dated as of December 31, 2001, between the Registrant and Joel Schoenfeld.
   

-27-



21.1(3)
List of Subsidiaries.
   
31.1(10)
Statement of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
 
31.2(10)
Statement of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
 
32.1(10)
Statement of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
 
 
32.2(10)
Statement of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
   


(1)
Incorporated by reference to the Registrant's Form 8K filed January 4, 2002.
   
(2)
Incorporated by reference to the Registrant's Form 8K filed March 11, 2002.
   
(3)
Incorporated by reference to the Registrant's Form 8K filed February 10, 2005.
   
(4)
Incorporated by reference to the Registrant's Form 8K filed June 13, 2005.
   
(5)
Incorporated by reference to the Registrant's Form 8K/A Amendment 2 filed January 11, 2006.
   
(6)
Incorporated by reference from the Registrant's Registration Statement on Form SB-2 (File No. 333-20187) declared effective on April 24, 1997.
 
 
(7)
Incorporated by reference from the Registrant's Periodic Quarterly Report on Form 10-QSB for the fiscal quarter ended September 30, 2000.
   
(8)
Incorporated by reference from the Registrant's Registration Statement on Form S-3 (File No. 333-62261) declared effective December 11, 1999.
   
(9)
Incorporated by reference from Amendment No. 2 to the Registrant's Registration Statement Form 10-S-3 (File 333-74199).
   
(10)
Incorporated by reference to the Registrant's Annual Report on Form 10-KSB for the year ended December 31, 1998 (File No. 0-22413).
   

-28-



(11)
Incorporated by reference from the Registrant's Post-Effective Amendment No 1 on Form S-2 to Form S-3 (File No. 333-74199) declared effective on January 26, 2001.
   
(12)
Incorporated by reference to the Registrant's Annual Report on Form 10-KSB for the year ended December 31, 2000 (File No. 0-22413).
   
(13)
Filed herewith.


(b) Reports on Form 8-K filed during the fourth quarter 2005.

No Forms 8-K were filed during the fourth quarter 2005.
 

Item 14. Principal Accountant Fees and Services.

The following table presents the cost of Univec's principal accountants' fees and services for the years ended December 31, 2005 and 2004, respectively:

 
  
2005
  
2004
  
Audit fees
  
$
153,240
  
$
110,261
  
Audit related fees
    
-
   
-
  
Tax fees
    
-
   
18,750
  
All other fees
    
-
   
-
  
Total
 
$
153,240
  
$
129,011
  

Univec's Audit Committee pre-approves the engagement of the principal accountant and the estimated audit fee, by each category.

-29-






SIGNATURES

In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the under-signed, thereunto duly authorized.

Dated: February 22,2007

UNIVEC, INC.

By: s/ Dr. David Dalton
Dr. David Dalton
Chief Executive Officer
(Principal Executive Officer)

In accordance with the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant on February 22, 2007 in the capacities indicated.
 
   UNIVEC, INC.  
 
 
 
 
 
 
 
By:  
/s/ Dr. David Dalton
 
Chief Executive Officer and a Director
(Principal Executive Officer)
 
 
 
 
 
 
 
 
By:  
/s/ Michael Lesisko
 
Chief Financial Officer, Treasurer, Secretary
 
 
 
 
 
 
 
 
By:  
/s/ S. Robert Grass
 
Chairman and a Director
 
-30-





 
UNIVEC, INC. AND SUBSIDIARIES
CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2005 AND FOR THE TWO YEARS THEN ENDED

Index to Consolidated Financial Statements


 
Page
 
 
 
 
Report of Independent Registered Public Accounting Firm
F--2
Consolidated Balance Sheet - December 31, 2005
F--3
Consolidated Statements of Operations - years ended
 
    December 31, 2005 and 2004
F--4
Consolidated Statements of Stockholders' Equity - years
 
    ended December 31, 2005 and 2004
F--5
Consolidated Statements of Cash Flows - years ended
 
    December 31, 2005 and 2004
F--6
Notes to Consolidated Financial Statements
F--7








 
 
Report of Independent Registered Public Accounting Firm
 

To the Board of Directors and
Stockholders of Univec, Inc.
 
We have audited the accompanying consolidated balance sheet of Univec, Inc. and Subsidiaries as of December 31, 2005 and the related consolidated statements of operations, stockholders' equity and cash flows for each of the years in the two-year period ended December 31, 2005. These consolidated financial statements are the responsibility of the Company's management.  Our responsibility is to express an opinion on these consolidated financial statements based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company’s internal control over financial reporting. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall consolidated financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Univec, Inc. and Subsidiaries as of December 31, 2005 and the consolidated results of their operations and their consolidated cash flows for each of the years in the two-year period ended December 31, 2005 in conformity with accounting principles generally accepted in the United States of America. 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has suffered from recurring losses from operations, has negative working capital, has a total stockholders’ deficit and is in default on certain debt, all of which raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also discussed in Note 2.  The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
 


Baltimore, Maryland          /s/ Abrams, Foster, Nole & Williams, P.A
November 15, 2006                     Abrams, Foster, Nole & Williams, P.A.
 
 
 
F-2



 

Univec, Inc. and Subsidiaries
  
 
  
 
 
  
December 31, 2005
  
 
  
 
  
 
  
ASSETS
  
 
  
Cash
  
$
991
  
Accounts receivable
    
174,864
 
Inventories
    
193,325
 
 
      
Total current assets
    
369,180
 
 
      
Fixed assets, net
    
520,092
 
Other assets
    
64,638
 
 
      
Total assets
  
$
953,910
  
 
      
LIABILITIES AND STOCKHOLDERS' DEFICIT
      
Accounts payable and accrued expenses
  
$
1,598,524
  
Deferred payroll
    
1,878,483
 
Notes and loans payable - current
    
890,438
 
Loans payable - officers/directors - current
    
258,300
 
Due to affiliated companies
    
815,510
 
 
      
Total current liabilities
    
5,441,255
 
 
      
Notes and loans payable - long-term
    
318,183
 
Loans payable - officers/directors - long term
    
50,000
 
 
      
Total liabilities
    
5,809,438
 
 
      
Commitments and contingencies (Notes 3, 4, 12 and 13)
      
 
      



STOCKHOLDERS' DEFICIT
  
 
  
Preferred stock $.001 par value; 3,743,500 shares
  
 
  
  authorized; none issued and outstanding
  
 
  
    Series D 5% cumulative convertible preferred stock,
  
 
  
      $.001 par value; authorized: 1,250,000; issued and
  
 
  
      outstanding: 208,333 shares (aggregate liquidation
  
 
  
      value: $554,272)
    
208
 
Series E cumulative convertible preferred stock,
      
      $.001 par value; authorized: 2,000 shares; issued and
      
      outstanding: 312 shares (aggregate liquidation
      
      value: $350,747)
    
1
 
Common stock $.001 par value; authorized: 75,000,000 shares;
    
57,634
 
      issued: 57,634,282 and outstanding: 57,230,128 shares
      
Additional paid-in capital
    
11,514,390
 
Treasury stock, 404,154 shares - at cost
    
(28,291
)
Accumulated deficit
    
(16,399,470
)
 
      
Total stockholders' deficit
    
(4,855,528
)
 
      
Total liabilities and stockholders' deficit
  
$
953,910
  
 
      
See notes to consolidated financial statements.
     
 
      

 
F-3



 
Univec, Inc. and Subsidiaries
Consolidated Statement of Operations
Years ended December 31, 2005 and 2004
 
  
2005
  
2004
  
 
  
 
  
 
  
Revenues (Note 4)
  
$
81,398
  
$
327,827
  
Cost of revenues
    
(3,164
)
  
128,933
 
 
          
Gross Margin
    
84,562
   
198,894
 
 
          
Operating Expenses
          
  Marketing and selling
    
233,990
   
123,400
 
  Product development
    
3,802
   
28,871
 
  General and administrative
    
1,535,840
   
1,772,246
 
  Loss on write-off of goodwill
    
0
    
1,774,119
  
 
    
1,773,632
   
3,698,636
 
 
          
Loss from Operations
    
(1,689,070
)
  
(3,499,742
)
 
          
Other Income (Expense)
          
  Interest expense, net
    
(200,019
)
  
(108,092
)
  Gain on extinguishments of debt
    
-
   
144,819
 
Other income
    
-
   
47,795
 
    Total other expenses
    
(200,019
)
  
84,522
  
 
          
Loss from continuing operations
    
(1,889,089
)
  
(3,415,220
)
 
          
Loss from discontinued operations
    
-
   
(8,260
)
Loss on sale of subsidiary
    
0
    
(597,056
)
 
          
Net loss
    
(1,889,089
)
  
(4,020,536
)
 
          
Dividends attributable to preferred stock
    
(34,844
)
  
(35,921
)
 
          
Loss attributable to common stockholders
  
$
(1,923,933
)
$
(4,056,457
)
 
          
Share information
          
  Basic net loss per common share
  
$
(0.04
)
$
(0.11
)
Basic weighted average number
         
of common shares outstanding
    
52,729,533
   
38,510,467
 
 
          
See notes to consolidated financial statements.
         
 
F-4



 
Univec, Inc. and Subsidiaries
Consolidated Statement of Stockholders' Equity
Years ended December 31, 2005 and 2004

 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
       
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
Additional
  
 
  
 
  
Prepaid
  
 
  
Total
  
 
  
Series D Preferred
  
Series E Preferred
  
Common Stock
  
Paid-in
  
Treasury Stock
  
Consulting
  
Accumulated
 
Stockholders'
  
 
  
Shares
  
Amount
  
Shares
  
Amount
  
Shares
  
Amount
  
Capital
  
Shares
  
Amount
  
Services
  
Deficit
  
Equity
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
Balance, January 1, 2004
    
104,167
  
$
104
    
492
  
$
1
    
35,168,476
  
$
35,169
  
$
10,506,007
                
($10,478,646
)
$
62,635
  
 
                                                  
Sale of Series D
    
20,833
    
21
                    
49,979
                    
50,000
  
Common stock issued for:
                                                  
  Cash
                                                  
  Consulting fees
                    
6,000,000
    
6,000
    
234,000
            
($240,000
)
        
  Deferred payroll and accrued
                                                 
      expenses - officers
                    
2,160,035
    
2,160
    
173,102
                    
175,262
  
  Loans payable - officers/directors
                    
500,000
    
500
    
9,500
                    
10,000
  
  Sale of subsidiary
                            
2,829
    
404,154
    
($28,291
)
          
(25,462
)
  Convert Series E and dividends
            
(80
)
      
1,790,341
    
1,790
    
(1,790
)
              
(3,168
)
  
(3,168
)
Amortization
                                        
30,000
       
30,000
 
Options issued
                            
4,000
                    
4,000
 
Net loss
                                            
(4,020,536
)
  
(4,020,536
)
 
                                                  
 
                                                  
Balance, December 31, 2004
    
125,000
   
125
   
412
   
1
   
45,618,852
   
45,619
   
10,977,627
   
404,154
   
(28,291
)
  
(210,000
)
  
(14,502,350
)
  
(3,717,269
)
 
                                                  
Sale of Series D
    
83,333
   
83
                   
199,917
                   
200,000
 
  Common stock issued for:
                                                  
  Cash
                    
350,000
   
350
   
34,650
                   
35,000
 
  Consulting fees
                    
1,500,000
   
1,500
   
43,500
                   
45,000
 
  Deferred payroll and accrued
                                                 
    expenses - officers
                    
5,640,882
   
5,641
   
185,189
                   
190,830
 
  Loans payable - affiliates
                    
2,333,333
   
2,333
   
67,667
                   
70,000
 
  Loans payable - officers/directors
                                                  
  Convert Series E and dividends
            
(100
)
      
2,191,215
   
2,191
   
5,840
               
(8,031
)
  
0
 
Amortization
                                        
210,000
       
210,000
 
Net loss
                                            
(1,889,089
)
  
(1,889,089
)
 
                                                  
 
                                                  
Balance, December 31, 2005
    
208,333
 
$
208
    
312
 
$
1
    
57,634,282
 
$
57,634
  
$
11,514,390
  
$
404,154
    
($28,291
)
$
0
    
($16,399,470
)
  
($4,855,528
)
 
 
F-5


 
Univec, Inc. and Subsidiaries
Consolidated Statement of Cash Flows
Years ended December 31, 2005 and 2004

 
  
2005
  
2004
  
Cash flows from operating activities
  
 
  
 
  
Net loss
  
$
(1,889,089
)
$
(4,020,536
)
Adjustments to reconcile net loss to net cash
          
  used in operating activities
          
  Loss on write-off of goodwill
    
-
   
1,774,119
 
  Loss on sale of subsidiary
    
-
   
481,719
 
  Depreciation and amortization
    
342,122
   
189,008
 
  Write-off of equipment
    
-
   
57,295
 
  Valuation allowance for inventories
    
-
   
75,000
 
  Stock based compensation
    
-
   
4,000
 
  Loss on cancellation of capital lease
    
-
   
(2,894
)
  Gain on extinguishment of debt
    
-
   
(98,547
)
  Gain on receipt of marketable securities
    
36,349
   
(36,349
)
  Other
    
-
   
(11,435
)
Changes in assets and liabilities, net of
          
  effects from sale of subsidiary -TWT
          
  Accounts receivable
    
3,098,629
   
(506,983
)
  Inventories
    
(13,447
)
  
17,698
 
  Other current assets and other assets
    
45,431
   
(3,320
)
  Accounts payable and accrued expenses
    
(2,629,243
)
  
713,610
 
  Deferred payroll
    
689,766
   
619,631
 
  Net cash used in operating activities
    
(319,482
)
  
(747,984
)
 
          
Cash flows from investing activities
          
  Purchases of fixed assets
    
(13,500
)
  
(397,068
)
  (Increase) decrease in restricted cash
    
340,407
   
(340,407
)
  Cash used in sale of subsidiary (net of notes and
          
  other payables of $103,600)
    
-
   
(5,670
)
  Net cash used in investing activities
    
326,907
   
(743,145
)
 
          
Cash flows from financing activities
          
  Proceeds from notes and loans payable,
          
  net of expenses of $80,146 in 2004
    
-
   
1,104,343
 
  Increase in due from affiliated companies
    
306,710
   
567,194
 
  Increase in loans payable - officers/directors
   
55,000
   
54,000
 
  Proceeds from sale of common stock
    
35,000
   
-
 
  Proceeds from sale of preferred stock
    
50,000
   
50,000
 
  Payments on notes and loans payable
    
(482,587
)
  
(242,386
)
  Payments of capitalized lease obligations
    
-
   
(21,232
)
  Dividends converted to preferred stock
    
-
   
(3,168
)
  Net cash provided by financing activities
    
(35,877
)
  
1,508,751
 
 
          
    Net increase (decrease) in cash
    
(28,452
)
  
17,622
 
Cash, beginning of period
    
29,443
   
11,821
 
Cash, end of period
  
$
991
  
$
29,443
  
Supplemental disclosure of cash flow information
          
  Cash paid for interest
  
$
87,667
  
$
48,709
  
Supplemental disclosures of noncash activity
          
  Common stock issued in payment of
          
  loans payable - officers/directors
  
$
0
  
$
10,000
  
Common stock and options issued in payment
  
$
262,837
    
179,262
 
  of deferred payroll and accrued expenses
          
Conversions of Series E to common stock,
         
  including dividends
 
$
8,031
  
$
3,168
  
Treasury stock received, net of options issued,
         
  on sale of subsidiary
  
$
0
    
(125,462
)
 
          
See notes to consolidated financial statements.
          
 
F-6


Notes to Consolidated Financial Statements

1. Nature of Operations

Univec, Inc. (Company) produces, licenses and markets medical products, primarily syringes, on a global basis. Physician and Pharmaceutical Services, Inc. (PPSI), a subsidiary, provides pharmaceutical sample and group purchasing services of pharmaceutical products. Thermal Waste Technologies, Inc. (TWT), a subsidiary until its sale, marketed a medical waste disposal unit.

2. Going Concern

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of December 31, 2005, the Company had negative working capital of $5,175,588 and stockholders' deficit of $4,959,041 and had incurred net losses of $(1,842,602) and $(4,020,536) for the years ended December 31, 2005 and 2004, respectively. These factors, among others, indicate that the Company's continuation as a going  concern is dependent upon its ability to obtain adequate financing and/or achieve profitable operations. The financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

Management is currently seeking additional investment capital to support its entrance into
new business ventures and provide the capital needed to operate.

3. Significant Accounting Policies

Basis of Presentation

The consolidated financial statements include all the accounts of the Company and its wholly-owned subsidiaries, Physician and Pharmaceutical Services, Inc. (PPSI), Thermal Waste Technologies, Inc. (TWT), until its sale and Rx Ultra, Inc. (inactive). All material inter-company balances and transactions have been eliminated. The consolidated financial statements include all the accounts of Thermal Waste Technologies, Inc. until its sale

Accounts Receivable

Accounts receivable consisted of receivables from customers. The Company records a provision for doubtful receivables, if necessary, to allow for any amounts which may be unrecoverable and is based upon an analysis of the Company's prior collection experience, customer creditworthiness, and current economic trends. As of December 31, 2005, no allowance was necessary.

Inventories

Inventories are valued at the lower of cost, determined by the first-in, first-out method, or market.

 
F-7




 
Fixed Assets

Fixed assets are stated at cost, less accumulated depreciation, and are depreciated on a straight-line basis over the estimated useful lives of seven years. Maintenance and repairs are charged to expense as incurred; renewals and improvements which extend the life of assets are capitalized. Upon retirement or disposal, the asset cost and related accumulated depreciation and amortization are eliminated from the respective accounts and the resulting gain or loss, if any, is included in the results of operations.

The carrying value of fixed assets is evaluated whenever changes in circumstances indicate the carrying amount of such assets may not be recoverable. If necessary, the Company recognizes an impairment loss for the difference between the carrying amount of the assets and their estimated fair value. Fair value is based on current and anticipated future undiscounted cash flows.

Shipping Income and Expense

Shipping income is included in product sales. Shipping expenses are included in marketing and selling. Shipping expense was $2,396 and $5,312 for the years ended December 31 2005 and 2004, respectively. The Company has included these immaterial shipping expenses in marketing and selling expenses on the consolidated statement of operations. This method is in accordance4 with Emerging Issues Task Force (EITF) Issue No. 00-10, paragraph 6.

Product Development

Research and development costs have been expensed as incurred.

Basic Loss per Share

Basic net loss per common share was computed based on the weighted average number of common shares outstanding during the year. Dilutive net loss per share has not been presented as they are anti-dilutive.

Revenue Recognition

Product sales are recognized when products are shipped. Although the Company warrants its products, it is unable to estimate the future costs relating to warranty expense and, as such, recognizes warranty expenses as incurred. Revenues for PPSI's group purchasing (GPO)service are recognized when the products are shipped.

The Company utilizes the net sales method of recognizing the amount of revenue from GPO product sales. This method is influenced by several factors as defined by EITF 99-19, which the Company’s market agreement has indicated to be in accordance with the net sales method. The suppliers maintain the general inventory risk until the point when the pharmaceutical drug is dispensed to the patient in compliance with the “just in time” inventory method.

F-8





As a result of the different circumstances related to the Company’s manufacture, procurement, distribution and physician sampling programs diverse financial accounting methods are utilized to recognize revenues from its various revenue sources. The Company’s manufacturing and specialty pharmaceutical drug distribution programs employ the “gross” method of recognizing revenue. However, because of the distinctive type of services provided to the customers, GPO and physician sampling programs utilize the “net” method of revenue recognition.

Distributor Arrangements

The Company markets its syringe products exclusively through distributors and various government agencies. Accounts receivable balances are payable within thirty days of shipment. Univec provides a product quality warranty on its products. The Company has never had any of its products returned due to product deficiencies. The products are priced under competitive arrangements with each customer. The product revenue recognition is based upon the prices charged to each customer. The Company has no price concessions which allow payments below the agreed prices.

Product Warranties

The Company provides a product warranty for the products sold. However, the Company has never had a product returned due to defective quality. Further, there are no warranty costs recognized in the years ended December 31, 2005 and 2004. The Company believes that because no warranty costs were incurred during any of the periods mentioned, there is no need to disclose any additional warranty cost policy or amounts.

Stock Based Compensation

Compensation cost for common stock, stock options, warrants, etc., issued to employees and non-employees is based on the fair value method. The corporate stock is publicly traded. In accordance with Statement of Financial Accounting Standards Board Statement Number 123, paragraph 47(d), the cost of such transactions are measured at the closing trade price of the common stock at the date of issue of the stock and stock options.

During the year ended December 31, 2005, 5,640,882 common shares valued at $190,830 were exchanged for $82,771 of payroll expenses plus $108,059 of employee benefit costs and other employee expenses. During the year ended December 31, 2004, 2,160,035 common shares valued at $175,262 were exchanged for $50,000 of payroll expenses plus $125,262 of employee benefit costs.


Income Taxes

Deferred income taxes have been provided for temporary differences between financial statement and income tax reporting under the liability method , using expected tax rates and laws that are expected to be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not , that the deferred tax assets will not be realized.

F-9






Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Fair Values

The carrying amounts of cash, accounts receivable, accounts payable and accrued expenses, notes and loans payable and deferred payroll approximate their fair values.

New Accounting Pronouncements

Financial Accounting Standards Board (FASB) Statement # 123R, Stock Based Compensation, is effective for the year ended December 31, 2006. The interpretive response states that a registrant should evaluate each new accounting standard to SEC Staff Accounting Bulletin Topic 11:M - Question 2 directs the registrant to determine the appropriate disclosure in the given circumstances. Univec, Inc. intends to adopt Statement # 123R, Stock Based Compensation, for the year ended December 31, 2006. This response also applies to the unaudited interim financial statements for the six months ended June 30, 2006.

Management does not believe that any other recently issued , but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.
 
4. Concentrations

Cash
From time to time, the Company maintains cash in financial institutions in excess of insured limits. In assessing its risk, the Company's policy is to maintain funds only with reputable financial institutions.
 
Revenue Recognition
As a result of the differing circumstances related to the Company’s manufacture, procurement, distribution and physician sampling programs, diverse financial accounting methods are utilized to recognize the revenue from its various financial sources.

The Company utilizes the “gross” sales method of recognizing the amount of revenue from its syringe manufacturing and specialty pharmaceutical drug product sales. This method is influenced by several factors as defined by EITF 99-19, which the Company’s market agreements indicate to be in accordance with the gross sales method. The most significant factor under these agreements include the Company’s retention of the inventory’s risk of loss for these products.

The GPO and physician sampling programs use the “net” method of revenue recognition. However, the Company remains as the primary credit obligor in these arrangements.
 

F-10






Purchases

During both 2005 and 2004, the Company purchased 99% of its pharmaceutical drugs for its group purchasing service (GPO) from one non-related vendor. The arrangement requires the Company to pay for the drugs within forty five days after the respective period month-end. As of December 31, 2005, accounts payable to that one vendor were 2% of total accounts payable.

5. Marketable Securities

As of December 31, 2004, marketable securities consisted of an investment in an equity security, with a fair market value of $36,349. Management classified the investment as available-for-sale. The Company received this security in December 2004 upon the conversion from a mutual to a stock insurance company in which Univec had owned a policy.

In January 2005, the security was sold for $36,101.
 
6. Inventories

Inventories consisted of the following:
 
Raw materials
  
$
158,499
  
Work-in-process
    
89,641
  
Finished goods
   
25,494
 
 
    
273,634
 
Less: allowance for valuation
    
(125,000
)
 
  
$
148,634
  

The Company provided a $0 and $75,000 valuation allowance in 2005 and 2004, respectively.

7. Fixed Assets

Fixed assets consisted of the following:
 
Equipment
  
$
1,114,284
  
Less: accumulated depreciation
    
594,192
 
 
  
$
520,092
  
 
As of December 31, 2004, the Company wrote-off fixed assets located at former suppliers with a cost of $371,764 and a net book value of $85,088.

Depreciation expense was $116,093 and $128,901 in 2005 and 2004, respectively. For the year ended December 31, 2005, fully depreciated assets were approximately $180,000.

F-11

 



 
8. Notes and Loans Payable

As of December 31, 2005, notes and loans payable consisted of:
 

Loan due to a shareholder through July, 2009,
  
 
  
   with interest at prime plus 2% (1)
 
$
500,000
  
Loans payable to agencies for economic
      
   development payable at $4,615 per month until
      
   July 2009, with interest at 4% per annum (1)
   
97,321
  
Loan payable to a vendor without specific
      
   payment terms or interest (2)
    
211,852
  
Loan payable to a vendor without, specific interest
   
135,000
  
Loan payable to a vendor due April 30, 2007
      
   with interest at prime plus 2% per annum
   
78,151
  
Notes payable with interest at 8%
    
85,000
  
Notes payable with interest at 12%,
      
   per annum
   
55,000
  
Notes payable to a shareholder's trusts, with interest
      
   at 12%, per annum (2)
    
27,000
  
Other
   
19,297
  
 
    
1,208,621
  
Less: Current portion of notes and loans payable
    
890,438
  
 
  
$
318,183
  
 
(1) On July 23, 2004, the Company borrowed an aggregate of $500,000 from the City of Baltimore Development Corporation and the Maryland Department of Business and Economic Development payable in aggregate remaining equal monthly installments of $4,615 over five years, with interest at 4%, per annum. Proceeds were used to purchase equipment of $450,000, which together with certain other equipment of the Company, collateralize the borrowings. Loans from certain officers and directors of approximately $180,000 have been subordinated.
 
As required under the borrowings, the Company has obtained a revolving line of credit of $500,000 from a stockholder of the Company under which the Company may borrow for working capital through July 22, 2009. Loans under the line bear interest at the prime rate, plus 2%, per annum, and may be converted into common stock at $.065, per share, as defined. The Maryland Department of Business and Economic Development has guaranteed 80% of the loan and interest thereon. In July 2004, the Company borrowed $500,000 under the line of credit. As of December 31, 2005, the interest rate was 9%, per annum. Financing expenses in connection with these borrowings were $80,146 and are being amortized over the term of the borrowings.
 
(2) Subject to forgiveness upon the vendor's sale of shares of the Company’s common stock.
 
F-12






9. Due to Affiliated Companies

Due to affiliated companies, owned by the chief executive officer of the Company, on demand, with interest at 10%, per annum.

10. Loans Payable - Officer/Directors

As of December 31, 2005, loans payable - officer / directors consisted of:

Note payable to the chief executive officer
  
 
  
and the chairman of the board of the
  
 
  
Company, due on demand, with interest
  
 
  
at prime, plus 2%, per annum (1)
  
$
200,000
  
Notes payable to a directors
   
108,300
  
 
  
$
308,300
  

(1) The same terms as an underlying borrowing from a bank and collateralized by certain equipment. As of December 31, 2005 the interest rate was 9%, per annum.

11. Income Taxes

The Company files consolidated income tax returns with its subsidiaries. Prior to its acquisition, PPSI was a Subchapter S Corporation.

As of December 31, 2005, the Company had net operating loss carry forwards of approximately $14,950,000 available to reduce future taxable income expiring through 2025, which may be limited due to ownership changes.

For the years ended December 31, 2005 and 2004, the Company's deferred tax benefits (expenses) were as follows:

 
  
2005
  
2004
  
Net operating loss carry forwards
  
$
632,000
  
$
615,000
  
Depreciation
   
7,000
    
191,000
 
Goodwill
   
(45,000
)
  
(19,000
)
Compensation
   
230,000
   
132,000
 
Inventory and equipment valuation
              
allowances
   
-
    
60,000
  
Valuation allowance
    
(824,000
)
  
(979,000
)
None
          
None
  

F-13







As of December 31, 2005, the tax effects of the components of deferred tax assets and liabilities were as follows:

Deferred tax assets
       
Net operating loss carry forwards
  
$
6,000,000
  
Compensation
   
712,000
  
Goodwill
   
509,000
  
 
        
Total deferred tax asset
    
7,221,000
 
 
        
Deferred tax liabilities
        
Depreciation
   
(91,000
)
 
        
Net deferred tax asset
    
7,130,000
 
 
        
Valuation allowance
    
(7,130,000
)
 
        
None
        

As of December 31, 2005, realization of the Company's net deferred tax asset of approximately $7,130,000 was not considered more likely than not and, accordingly, a valuation allowance of $7,130,000 was provided.

The following is a reconciliation of expected income tax benefit utilizing the Federal statutory tax rate to income tax benefit reported on the statement of operations.

 
  
2005
  
2004
  
 
  
 
  
 
  
Expected income tax benefit
 
$
(632,000
)
$
(437,000
)
Change in valuation allowance arising in current year
   
1,233,000
    
1,164,000
  
State income tax benefit, net of federal income tax effect
   
(120,000
)
  
(107,000
)
Other
   
(481,000
)
  
(620,000
)
None
          
None
  

 
F-14



 

12. Commitments and Contingency

Lease

The Company was committed under a non-cancelable lease for production, storage and office space through July 2005. The lease provides for minimum annual rent of $72,000, additional rents for the Company's share of normal maintenance plus its pro-rata share of real estate taxes and eight one year renewals at the Company's option. This lease was terminated on February 6, 2006.

For 2005 and 2004, total rent expense was $72,000 and $78,000, respectively.

Employment Agreement

The Company is committed under an employment agreement to the chief executive officer, through January 2005, requiring annual compensation to be determined annually by the officer and Company. Annually, the agreement shall automatically renew for one year, resulting in a new three year term each January 1. For the years ended December 31, 2005 and 2004, the compensation was $435,600 and $396,000, respectively, which have been fully deferred by the chief executive officer. The agreement also provides for bonuses, as determined by the officer and the Company, an automobile allowance (of $24,000, per annum, for 2005) and life, disability and health insurance. In addition, the officer was granted options to purchase 2,000,000 shares of common stock exercisable at $.24, per share, through 2012. The options vest 25% on January 1, 2003 and 41,667 during each subsequent month.

13. Litigation Reserve

In December 2003, the Company assigned certain of their patents, earned royalties of $72,125 and 85% of all future royalties being earned from these patents in payment of a note payable and interest thereon for an aggregate of $99,434, in settlement to a collection matter. The Company recognized a $24,872 gain upon extinguishment of the debt. The Company in turn received relief from the restrictive patent payments and a perpetual license to exploit, market and manufacture these patents in North America. As the value of the license received could not be determined, no value was assigned to them.

In March 2004, the Company settled a collection matter with a former consultant in the amount of $165,000, payable in varying amounts through March 2007 and options to purchase 359,375 shares of common stock of the Company, all of which have been accrued as of December 31, 2003.

In February 2000, a former consultant commenced an action against the Company and its directors, alleging breach of contract and fiduciary duty, and is seeking consulting fees in the amount of: (1) 250,000 shares of common stock, (2) $192,000 and (3) costs of this action. The Company and counsel do not believe the consulting fees are due and will continue to vigorously defend this action.

F-15

 




14. Stockholders' Equity

Common Stock

During the year ended December 31, 2004, the Company issued an aggregate of 2,660,034 shares of common stock to a stockholder and three officers in payment of notes and loans of $10,000, deferred payroll of $$50,000 and benefits of $125,262.
 
In November 2004, the Company exchanged 6,000,000 shares of common stock for $240,000 of professional consulting services over a one-year term.

On April 6, 2005, the Company issued 1,386,527 common shares to a preferred stockholder in exchange for 70 shares of Series E preferred stock and unpaid dividends worth an aggregate of $5,843.

On June 28, 2005, the Company issued 1,896,970 shares of common stock to two officers in exchange for operating expenses incurred by them but not previously paid.

On June 29, 2005, the Company issued 1,500,000 shares of common stock to an independent marketing consultant in exchange for fees not paid of $45,000.

On June 30, 2005, the Company issued 1,286,082 shares of common stock to an officer/director of the Company in exchange for benefits not taken of $42,441.
 
On June 30, 2005, the Company converted $70,000 of notes payable to an affiliate owned by an executive officer in exchange for 2,333,333 shares of common stock.

On October 10, 2005, the Company issued 1,169,850 shares of common stock to an officer/director of the Company in exchange for benefits not taken of $12,868.
 
 
F-16



 

Preferred Stock
 
Series D
The Company has designated 1,250,000 shares of 5% cumulative convertible preferred stock (Series D), which are entitled to receive, prior to the payment of dividends to the common stock, cumulative dividends of 5%, per share, per annum. The Series D stock may be redeemed at the option of the Company, in cash at $2.40, per share. In addition, Series D stockholders are entitled to a liquidation preference of $2.40, per share, plus unpaid dividends. Each share of Series D is initially convertible into three shares of common stock.

During December 2004 and again during March, 2005 the Company sold 20,833 shares of Series D preferred stock to a customer for $50,000 for each respective group of20,833 shares. At December 31, 2005, another $150,000 is receivable from the shareholder for Series D stock purchase commitments due under this agreement.

Series E
In August 2003, the Company designated 2000 shares of 5% cumulative convertible preferred stock (Series E), which are entitled to receive, prior to the payment of dividends to the Series D and common stock, cumulative dividends of 5%, per share, per annum. The Series E stock may be redeemed at the option of the Company, in cash, at 135% of the stated value, per share, plus all unpaid dividends. In addition, Series E stockholders are entitled to a liquidation preference of $1,000, per share, plus all unpaid dividends. Each share of Series E is convertible into shares of common stock at the lesser of $1.10 or 80% of market value, as defined. In August 2006, the Company is required to convert all the Series E into common stock at the conversion price, unless the holder becomes a 5% or greater stockholder. The Company may redeem the Series E in cash at $1,350, per share, plus all unpaid dividends, as defined.

On August 5, 2003, the Company exchanged 122 shares of Series B and 250 shares of Series C, all the outstanding shares, for 522 shares of Series E.

In 2005 and 2004, 100 and 80 shares, respectively of Series E were converted into 2,191,215 and 1,790,431 shares of common stock at prices ranging from $.03 to $.06, per share.

Holders of preferred shares have no voting rights.

As of December 31, 2005, cumulative dividends in arrears on preferred
stock were:
 
Series D
  
$
54,272
  
Series E
    
38,747
  
 
  
$
93,019
  

F-17





Non Plan Options

During the year ended December 31, 2004, the Company issued options to purchase an aggregate of 1,050,000 shares of common stock of the Company to two officers and an employee. The options are exercisable at $.04, per share, through December 2009 and were valued at $4,000.

During the year ended December 31, 2005, the Company issued no options to purchase common stock of the Company

During 2005 and 2004, options to purchase 802,236 and 4,850,000 shares, respectively, of common stock expired or were cancelled without being exercised.
 
Reserved Shares

As of December 31, 2005, the Company has reserved shares of common stock as follows:

 
Non-plan options and warrants
    
7,446,862
  
Options under the Plans
    
685,000
  
Series D conversions
   
350,000
  
Series E conversions(a)
    
17,537,350
  
Litigation
    
250,000
  
 
    
26,269,212
  

(a) assumes conversions as of December 31, 2005 at $.02, per share.
 
15. Stock Option Plans

The 1996 Stock Option Plan (96 Plan) is administered by the Board of Directors or a committee thereof and options to purchase 4,709,219 shares of common stock may be granted under the Plan to directors, employees (including officers) and consultants to the Company. The Plan authorizes the issuance of incentive stock options (ISO's), as defined in Section 422A of the Internal Revenue Code of 1986, as amended, and non-qualified stock options (NQSO's). Consultants and directors who are not also employees of the Company are eligible for grants of only NQSOs. The exercise price of each ISO may not be less than 100% of the fair market value of the common stock at the time of grant, except that in the case of a grant to an employee who owns 10% or more of the outstanding stock of the Company or a subsidiary or parent of the Company, the exercise price may not be less than 110% of the fair market value on the date of grant. The aggregate fair market value of the shares covered by ISO's granted under the Plan that become exercisable by a Plan participant for the first time in any calendar year is subject to a $100,000 limitation. The exercise price of each NQSO is determined by the Board, or committee thereof, in its discretion; provided that NQSO's granted a 10% Stockholder be no less than 110% of the fair market value on the date of grant.
 
Under the 1998 Stock Option Plan (98 Plan), the Company may grant options to purchase 300,000 shares of common stock to employees, directors, independent contractors and consultants of the Company. The 98 Plan is similar to the Plan and authorizes the issuance of ISO's, NQSO's and Stock Appreciation Rights.

F-18





Under the 2000 Stock Option Plan (2000 Plan), the Company may grant options to purchase 2,000,000 shares of common stock to employees, directors, independent contractors and consultants of the Company. The Plan includes options to purchase an addition 250,000 shares of common stock, reserved for an Industrial and Scientific Advisory Committee to be formed as necessitated by the Company.

 The following table summarizes the activity of the Plans for 2005 and 2004.


 
  
2005
  
2004
  
 
  
 
  
Weighted
       
Weighted
  
 
       
Average
       
Average
  
 
       
Exercise
       
Exercise
  
 
  
Shares
  
Price
  
Shares
  
Price
  
 
                      
Options outstanding, beginning of year
   
1,335,000
  
$
0.70
    
1,335,000
  
$
0.70
  
Granted
   
None
    
-
    
None
    
-
  
Canceled, exercised, expired or exchanged
   
(650,000
)
$
0.675
    
None
    
-
  
Options outstanding, end of year
   
685,000
  
$
0.72
    
1,335,000
  
$
0.70
  
Options exercisable, end of year
   
685,000
  
$
0.72
    
1,335,000
  
$
0.70
  
Options available for grant, end of year
   
1,050,000
          
1,050,000
        
Weighted-average fair value of options granted
                          
during the year
 
$
.00
        
$
.00
        

The following table summarizes information about stock options outstanding under the Plan at December 31, 2005:


 
 
Weighted
 
 
 
 
Average
 
Weighted
 
 
Remaining
 
Average
Range of
Outstanding
Contractual
Exercisable
Exercisable
Exercise Prices
Options
Life (Years)
Options
Price
$3.50
65,000
1.50
65,000
$3.50
$2.00
70,000
2.00
70,000
$2.00
$0.50
100,000
5.25
100,000
$0.50
$0.24
35,000
7.00
35,000
$0.24
$0.20
60,000
0.75
60,000
$0.20
$0.15
355,000
4.50
355,000
$0.15
$0.15 to $3.50
685,000
2.70
685,000
$0.72

 

F-19

 




16. Sales of Technology

Through September 1, 2003, the Company licensed the non-exclusive, Worldwide use of the Company's patents for the manufacture, use and marketing of its auto-disable syringes providing for royalties on sales. In December 2003, the Company sold this license and assigned certain patents to a creditor in payment of $99,433 and also assigned certain future royalties under the auto-disable syringe licensing agreement. The Company has licensed back the rights under these patents to market and manufacture in North America.
 
17. Discontinued Operations
 
On August 16, 2004, in settlement of litigation, the Company sold TWT, a wholly-owned subsidiary, to an officer of the Company and his related parties, all former owners of TWT, in exchange for 404,154 shares of common stock of the Company, cancellation of deferred compensation to the officer of $221,042 and cancellation of the officer’s employment agreement. In addition, the officer received options to purchase 97,710 shares of common stock of the Company, exercisable at $.01, per share, for 10 years and the other purchasers received option to purchase 296,444 shares of common stock of the Company, exercisable at $.07, per share, for 10 years. The officer also will receive $100,000 in cash, payable in monthly installments of $10,000, commencing August 2004 and medical insurance payments of $3,600.
 
Expenses in connection with the sale were $87,307.
 

18 Goodwill

Goodwill had represented the excess purchase prices paid by the Company over the fair value of the tangible and other intangible assets and liabilities at the dates of acquisitions. Goodwill had not been amortized, but instead was subject to an annual assessment of impairment by applying a fair-value based test. The Company evaluated the carrying value of goodwill as of December 31, 2004. During the year ended December 31, 2004. The Company determined the carrying value of goodwill has been fully impaired and wrote-off the carrying value of $1,774,119.

In accordance with Statement of Financial Accounting Standards No. 142 Goodwill and Other Intangible Assets, paragraph 47(a) and 47(b), the Company determined that because the entire balance of this goodwill had ceased being of any economic value to the Company the entire carrying value of the asset was subject to write-off. The Company determined that this goodwill was providing no economic value and therefore in accordance with the provisions of Financial Accounting Standards No. 142, the entire economic value of the asset was written-off.


F-20





19. Subsequent Events

Common Stock

In February 2006, the Company issued an aggregate of 1,410,639 shares of common stock to an executive officer of the Company in exchange for accrued employment contract benefits of $29,842.

In July 2006, the Company issued an aggregate of 3,264,669 shares of common stock to an executive officer of the Company in exchange for accrued employment contract benefits of $42,441.

On July 31, 2006 the Company completed the private placement of a $2,000,000 6% Note Warrants Securities Purchase Agreement. The Agreement allows the investor to purchase 10,000,000 common stock warrants for seven years at an exercise price of $0.02 each. The Notes and Warrants were issued in reliance upon exemptions from regulation pursuant to section 4(2) of the Securities Act of 1933 and Regulation 506 of Regulation D promulgated thereto. Each of the Investors is an accredited investor as defined in Rule 501 of Regulation D under the Securities Act of 1933.

The initial closing was for financing of the principal amount of $700,000 for which callable secured convertible notes were issued. Under the securities purchase agreement, the principal amount of $600,000 is be received when the SB-2 registration statement is filed with the SEC. The final amount of $700,000 is to be received when the registration statement is declared effective. At both times, callable secured convertible notes will be issued for such amounts. The note is convertible into the Company’s common shares at the lowest three intra-day trading prices during the twenty trading days immediately prior to the conversion date as discounted by 40%. The investors in the financing shall not be entitled to convert the promissory note if such conversion would result in any investor solely owning more than 4.99% of the outstanding common shares of the Company

The Notes carry an interest rate of 6% per annum and a maturity date of July 31, 2009. The notes are convertible into our common shares at the Applicable Percentage of the average of the lowest three (3) trading prices for our shares of common stock during the twenty (20) trading day period prior to conversion. The “Applicable Percentage” means 50%; provided, however, that the Applicable Percentage shall be increased to (i) 55% in the event that a Registration Statement is filed within thirty days of the closing and (ii) 60% in the event that the Registration Statement becomes effective within one hundred and twenty days from the Closing.

At our option, we may prepay the Notes in the event that no event of default exists, there are a sufficient number of shares available for conversion of the Notes and the market price is at or below $.25 per share. In addition, in the event that the average daily price of the common stock, as reported by the reporting service, for each day of the month ending on any determination date is below $.25, we may prepay a portion of the outstanding principal amount of the Notes equal to 101% of the principal amount hereof divided by thirty-six (36) plus one month’s interest. Exercise of this option will stay all conversions for the following month. The full principal amount of the Notes is due upon default under the terms of Notes. In addition, the Company has granted the investors a security interest in substantially all of its assets and intellectual property as well as registration rights.

The Investors have contractually agreed to restrict their ability to convert the Notes and exercise the Warrants and receive shares of the Company's common stock such that the number of shares of the Company's common stock held by them and their affiliates after such conversion or exercise does not exceed 4.99% of the then issued and outstanding shares of the Company's common stock.

F-21






Based on this recent financing, we have also issued 10,000,000 warrants convertible into shares of the Company’s common stock. Each warrant entitles the holder to one share of common stock. The exercise price is $0.02 per share and is exercisable for seven years from the date of issuance. The warrants have a cashless exercise feature. For the 10,000,000 warrants issued on July 31, 2006, the expiration date is July 31, 2013.

The convertible notes and warrants (the “Securities”) were issued in reliance on the exemption from registration provided by Section 4(2) of the Securities Act. No commission was paid for the issuance of such Securities. The above issuance of Securities qualified for exemption under Section 4(2) of the Securities Act since the issuance of such shares by the Company did not involve a public offering. The holders of these Securities were each accredited.

None of the Securities has been converted to common stock as yet. The Securities have been recoded as convertible debt payable by the Company.

As defined by EITF 00-19, paragraph 12 to 32, because the Contracts include a provision that could require net-cash settlement then the contracts cannot be accounted for as equity of the Company (that is liability classification is required for such contracts). Further, the Company has concluded that this obligation qualifies as conventional convertible debt.

As provided by SFAS No. 133 and EITF Issue 11-19, because the warrants are not a hedging instrument, the gain or loss resulting from changes in the fair value of the instrument are to be recognized in earnings of the period of the change in value.

Because the Callable Convertible Secured Notes and warrants were not issued until July 31, 2006, their value has not been included in the financial statements of the Company at June 30, 2006

Due to Affiliated Companies and Officers

Subsequent to December 31, 2005, the Company borrowed an additional $4,208 from the affiliated companies.

F-22



 
Note 20 Selected Quarterly Financial Data
 
20. Selected Quarterly Financial Data - 2005 (Unaudited)
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
Univec, Inc. and Subsidiaries
  
 
  
 
  
 
  
 
  
Balance Sheets
  
 
  
 
  
 
  
 
  
 
       
 
  
 
  
 
  
 
  
December 31, 2005
  
September 30, 2005
  
June 30, 2005
  
March 31, 2005
  
   
 (As Restated)
  
 (As Restated)
  
 (As Restated)
  
 (As Restated)
  
Assets
  
 
  
 
  
 
  
 
  
  Cash
  
$
991
  
$
3,301
  
$
2,970
  
$
10,079
  
  Accounts receivable
    
174,864
   
970,529
   
3,066,601
   
2,956,590
 
  Inventories
    
193,325
   
179,877
   
179,878
   
179,878
 
  Certificates of Deposit -
                  
    Restricted
        
348,949
   
340,407
   
340,407
 
  Other current assets
                
5,967
 
  Total current assets
    
369,180
   
1,502,656
   
3,589,856
   
3,492,921
 
  Fixed assets - net
    
520,092
   
542,031
   
578,139
   
606,185
 
  Other assets
    
64,638
   
67,310
   
70,117
   
75,461
 
Total assets
  
$
953,910
  
$
2,111,997
  
$
4,238,112
  
$
4,174,567
  
 
                  
Liabilities and Stockholders Deficit
                  
  Accounts payable &
                 
    accrued expenses
  
$
1,598,524
  
$
2,310,356
  
$
4,279,589
  
$
4,180,057
  
  Deferred payroll
    
1,878,483
   
1,711,081
   
1,535,309
   
1,354,639
 
  Notes and loans pay
                 
    - current
    
890,438
   
1,334,446
   
1,337,946
   
1,417,199
 
  Loans payable -
                 
    officers/directors
    
258,300
   
265,493
   
260,493
   
260,493
 
  Due to affiliated
                 
    companies
    
815,510
   
752,360
   
684,175
   
685,225
 
Total current liabilities
    
5,441,255
   
6,373,736
   
8,097,512
   
7,897,613
 
  Notes and loans
                  
    payable - long-term
    
318,183
   
216,332
   
258,352
   
211,152
 
  Loans payable -
                 
    officers/directors long-term
    
50,000
    -     -     -  
Total liabilities
    
5,809,438
   
6,590,068
   
8,355,864
   
8,108,765
 

F-23






Stockholders’ deficit
 
 
 
 
 
 
 
 
 
 
 
 
 
  Preferred stock - D
 
 
208
 
 
146
 
 
146
 
 
146
 
  Preferred stock - E
 
 
1
 
 
1
 
 
1
 
 
1
 
  Common stock
 
 
57,634
 
 
56,464
 
 
56,465
 
 
48,062
 
  Additional paid-in
 
 
 
 
 
 
 
 
 
 
 
 
 
    capital
 
 
11,514,390
 
 
11,352,754
 
 
11,352,754
 
 
11,135,273
 
  Treasury stock
 
 
(28,291
)
 
(28,291
)
 
(28,291
)
 
(28,291
)
  Stock subscription
 
 
 
 
 
(30,000
)
 
(90,000
)
 
(150,000
)
  Accumulated deficit
 
 
(16,399,470
)
 
(15,829,145
)
 
(15,408,827
)
 
(14,939,389
)
Total stockholders'
 
 
 
 
 
 
 
 
 
 
 
 
 
    deficit
 
 
(4,855,528
)
 
(4,478,071
)
 
(4,117,752
)
 
(3,934,198
)
Total liabilities and
 
 
 
 
 
 
 
 
 
 
 
 
 
    stockholders deficit
 
$
953,910
 
$
2,111,997
 
$
4,238,112
 
$
4,174,567
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

F-24






20. Selected Quarterly Financial Data - 2004 (Unaudited)
  
 
  
 
  
 
  
 
  
Univec, Inc. and Subsidiaries
  
 
  
 
  
 
  
 
  
Balance Sheets
  
 
  
 
  
 
  
 
  
 
  
December 31, 2004
  
 September 30, 2004
  
 June 30, 2004
  
 March 31, 2004
  
   
 (As Restated)
  
 (As Restated)
  
 (As Restated)
  
 (As Restated)
  
Assets
  
 
  
 
  
 
  
 
  
  Cash
  
$
29,443
  
$
8,024
  
$
49,162
  
$
852
  
  Marketable securities
    
36,349
                    
  Accounts receivable
    
3,123,493
    
1,628,446
    
1,508,933
    
1,472,635
  
  Inventories
    
179,878
    
269,672
    
301,913
    
295,248
  
  Certificates of Deposit -
                  
    Restricted
    
340,407
    
335,000
    
335,000
        
  Other current assets
    
46,630
    
83,341
    
96,297
    
124,888
  
  Total current assets
    
3,756,200
    
2,324,483
    
2,291,305
    
1,893,623
  
  Fixed assets - net
    
622,685
    
894,802
    
542,401
    
587,598
  
  Goodwill
          
1,774,119
    
2,328,662
    
2,328,662
  
  Other assets
    
79,468
    
83,475
    
6,000
    
6,000
  
Total assets
  
$
4,458,353
  
$
5,076,879
  
$
5,168,368
  
$
4,815,883
  
Liabilities and Stockholders Deficit
                  
  Accounts payable &
                 
    accrued expenses
  
$
4,380,826
  
$
2,946,251
  
$
2,877,647
  
$
2,762,038
  
  Deferred payroll
    
1,271,488
   
1,092,697
   
1,261,588
   
1,064,292
  
  Notes and loans pay
                 
    - current
    
1,472,163
   
1,065,795
   
350,872
   
166,376
  
  Loans payable -
                 
    officers/directors
    
260,493
    
260,493
    
270,493
    
270,493
  
  Due to affiliated
                 
    companies
    
578,800
    
504,643
    
663,452
    
328,017
  
Total current liabilities
    
7,963,770
    
5,869,879
    
5,424,052
    
4,591,216
  
  Notes and loans
                  
    payable - long-term
    
211,852
    
696,814
    
409,051
    
497,033
  
Total liabilities
    
8,175,622
    
6,566,693
    
5,833,103
    
5,088,249
  
Stockholders’ deficit
                  
  Preferred stock - D
   
125
    
104
    
104
    
104
  
  Preferred stock - E
    
1
   
1
   
1
   
1
 
  Common stock
    
45,619
    
38,628
    
37,872
    
37,872
  
  Additional paid-in
                  
    capital
    
10,977,627
    
10,690,639
    
10,661,408
    
10,661,408
  
  Treasury stock
    
(28,291
)
  
(28,291
)
            
  Stock subscription
   
(210,000
)
                  
  Accumulated deficit
    
(14,502,350
)
  
(12,190,895
)
  
(11,364,120
)
  
(10,971,751
)
Total stockholders'
                  
    deficit
    
(3,717,269
)
  
(1,489,814
)
  
(664,735
)
  
(272,366
)
Total liabilities and
                  
    stockholders deficit
  
$
4,458,353
  
$
5,076,879
  
$
5,168,368
  
$
4,815,883
  
 
                  
F-25



20. Selected Quarterly Financial Data - 2005 (Unaudited)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Univec, Inc. and Subsidiaries
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Statements of Operations
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Year ended
    
Three months ended
    
Nine months ended
    
Three months ended
    
Six months ended
    
Three months ended
    
Three months ended
 
 
 
 
Dec. 31, 2005
    
Dec. 31, 2005
    
Sept. 30, 2005
    
Sept. 30, 2005
    
June 30, 2005
    
June 30, 2005
    
March 31, 2005
 
     
(As Restated)
    
(As Restated)
    
(As Restated)
    
(As Restated)
    
(As Restated)
    
(As Restated)
    
(As Restated)
  
Revenues
 
$
81,398
 
$
3,014
 
$
78,384
 
 
($6,683
)
$
85,067
 
$
45,056
 
$
40,011
 
Cost of revenues
 
 
3,164
 
 
9,176
 
 
(6,012
)
 
17,135
 
 
(23,147
)
 
(8,201
)
 
(14,946
)
Gross margin
 
 
84,562
 
 
12,190
 
 
72,372
 
 
10,452
 
 
61,920
 
 
36,855
 
 
25,065
 
Operating expenses
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Marketing and selling
 
 
(233,990
)
 
(1,015
)
 
(232,975
)
 
(74,897
)
 
(158,078
)
 
(65,988
)
 
(92,090
)
  Product development
 
 
(3,802
)
 
(3,154
)
 
(648
)
 
0
 
 
(648
)
 
(648
)
 
 
 
  General & administrative
 
 
(1,535,840
)
 
(524,333
)
 
(1,011,507
)
 
(283,161
)
 
(728,346
)
 
(389,941
)
 
(338,405
)
  Total operating expenses.
 
 
(1,773,632
)
 
(528,502
)
 
(1,245,130
)
 
(358,058
)
 
(887,072
)
 
(456,577
)
 
(430,495
)
Loss from operations
 
 
(1,689,070
)
 
(516,312
)
 
(1,172,758
)
 
(347,606
)
 
(825,152
)
 
(419,722
)
 
(405,430
)
Other income (expense)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Interest expense, net
 
 
(200,019
)
 
(54,012
)
 
(146,007
)
 
(72,712
)
 
(73,295
)
 
(43,874
)
 
(29,421
)
    Total other income
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    (expense)
 
 
(200,019
)
 
(54,012
)
 
(146,007
)
 
(72,712
)
 
(73,295
)
 
(43,874
)
 
(29,421
)
Net loss
 
 
(1,889,089
)
 
(570,324
)
 
(1,318,765
)
 
(420,318
)
 
(898,447
)
 
(463,596
)
 
(434,851
)
Dividends attributable to
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  preferred stock
 
 
(34,844
)
 
(9,704
)
 
(26,631
)
 
(8,213
)
 
(18,418
)
 
(8,213
)
 
(10,205
)
Loss attributable to
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  common stockholders
 
 
($1,923,933
)
 
($502,810
)
 
($1,345,396
)
 
($428,531
)
 
($916,865
)
 
($471,809
)
 
($445,056
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F-26





Basic net loss per share
 
 
($0.04
)
 
($0.01
)
 
($0.03
)
 
($0.01
)
 
($0.02
)
 
($0.01
)
 
($0.01
)
Basic weighted average
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  number common
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  shares outstanding
 
 
52,729,533
 
 
57,634,282
 
 
50,999,828
 
 
56,464,432
 
 
48,222,239
 
 
49,500,728
 
 
47,330,653
 
F-27

 


 
 
20. Selected Quarterly Financial Data - 2004 (Unaudited)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Univec, Inc. and Subsidiaries
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Statements of Operations
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Year ended
    
Three months ended
    
Nine months ended
    
Three months ended
    
Six months ended
    
Three months ended
    
Three months ended
 
 
 
 
Dec. 31, 2004
    
Dec. 31, 2004
    
Sept. 30, 2004
    
Sept. 30, 2004
    
June 30, 2004
    
June 30, 2004
    
March 31, 2004
 
     
(As Restated
    
(As Restated)
    
(As Restated)
    
(As Restated)
    
(As Restated)
    
(As Restated)
    
(As Restated)
  
Revenues
 
$
327,827
 
$
31,658
 
$
296,169
 
 
99,631
  
$
196,538
 
$
171,688
 
$
24,850
 
Cost of revenues
 
 
(128,933
) 
 
(71,997
) 
 
(56,936
)
 
(33,861
) 
 
(23,075
)
 
(38,511
)
 
(15,436
)
Gross margin
 
 
198,894
 
 
(40,339
) 
 
239,233
 
 
65,770
 
 
173,463
 
 
133,177
 
 
40,286
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Operating expenses
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Marketing and selling
 
 
(123,400
)
 
(7,986
)
 
(115,414
)
 
14,052
  
 
(129,466
)
 
(5,328
)
 
(124,138
)
Product development
 
 
(28,871
)
 
(609
)
 
(28,262
)
 
(25,530
)
 
(2,732
)
 
(1,886
)
 
(846
)
General & administrative
 
 
(1,772,246
)
 
(457,965
)
 
(1,314,281
)
 
(393,881
)
 
(920,400
)
 
(486,329
)
 
(434,071
)
Loss on write-off of goodwill
    
(1,774,119
)
  
(1,774,119
)
   -      -      -      -      -  
Total operating expenses.
 
 
(3,698,636
)
 
(2,240,679
)
 
(1,457,957
)
 
(405,359
)
 
(1,052,598
)
 
(493,543
)
 
(559.055
)
Loss from operations
 
 
(3,499,742
)
 
(2,281,018
)
 
(1,218,724
)
 
(339,589
)
 
(879,135
)
 
(360,366
)
 
(518,769
)
Other income (expense)
 
 
                                      
 
Interest expense, net
 
 
(108,092
)
 
(23,288
)
 
(84,804
)
 
(38,424
)
 
(46,380
)
 
(32,003
)
 
(14,377
)
Gain on extinguishment of debt
    
144,819 
 
 
64,225 
 
 
80,594 
 
 
40,554 
 
 
40,400 
 
 
-
 
 
40,400 
  
Other income (expense)
    
47,795
    
47,795
                                
Total other income (expense)
 
 
84,522
  
 
88,732
  
 
(4,210
)
 
2,130
  
 
(6,340
)
 
(32,003
)
 
25,663
 
Loss from continuing operations
 
 
(3,415,220
)
 
(2,192,284
)
 
(1,222,934
)
 
(337,459
)
 
(885,475
)
 
(392369
)
 
(493,106
)

F-28




Loss from discontinued operations
                                            
Discontinued operating losses
    
(8,260
)
        
(8,260
)
  
(8,260
)
                  
Loss on sale of subsidiary
    
(597,056
)
  
(116,000
)
(481,
(481,056
)
  
(481,056
)
   -      -     -  
Net loss
    
(4,020,536
)
  
(2,308,286
)
  
(1,712,250
)
  
(826,775
)
  
(885,475
)
  
(392,369
)
  
(493,106
)
Dividends distributable to
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
preferred stock
 
 
(35,921
)
 
(8,721
)
 
(27,200
)
 
(8,650
)
 
(18,550
)
 
(9,275
)
 
(9,275
)
Loss attributable to common
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
stockholders
 
 
($4,056,457
)
 
($2,317,007
)
 
($1,739,450
)
 
($835,425
)
 
($904,025
)
 
($401,644
)
 
($502,371
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Basic net loss per share
 
 
($0.11
)
 
($0.06
)
 
($0.05
)
 
($0.02
)
 
($0.02
)
 
($0.01
)
 
($0.01
)
Basic weighted average number
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
common shares
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
outstanding
 
 
38,510,467
 
 
39,393,090
 
 
37,394,433
 
 
38,244,097
 
 
36,952559
 
 
37871795
 
 
35,331,157
 
 
F-29






20. Selected Quarterly Financial Data - 2005 (Unaudited)
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
Univec, Inc. and Subsidiaries
  
 
  
 
  
 
  
 
  
Statement of Cash Flow
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
Year Ended
  
 Nine Months Ended
  
 Six MonthsEnded
  
 Three Months Ended
  
 
  
December 31, 2005
  
 September 30, 2005
  
 June 30, 2005
  
 March 30, 2005
  
   
 (As Restated)
  
 (As Restated)
  
 (As Restated)
  
 (As Restated)
  
Cash flows from operating activities
  
 
  
 
  
 
  
 
  
Net loss
    
($1,889,089
)
  
($1,318,765
)
  
($898,447
)
  
($434,851
)
Adjustments to reconcile net loss to net cash
                  
  used in operating activities
                  
  Depreciation and amortization
    
342,122
   
286,312
   
187,397
   
94,007
 
  Stock based compensation
    
167,198
   
167,198
   
167,198
     
  Gain on receipt of marketable securities
    
36,349
   
36,349
   
36,349
   
36,349
 
Changes in assets and liabilities, net
                  
  Accounts receivable
    
3,098,629
   
2,152,963
   
56,891
   
166,902
 
  Inventories
    
(13,447
)
            
  Other current assets and other assets
    
45,431
   
46,630
   
46,630
   
40,663
 
  Accounts payable and accrued expenses
    
(2,629,243
)
  
(2,097,474
)
  
(128,241
)
  
(210,617
)
  Deferred payroll
    
522,068
   
522,364
   
346,592
   
165,922
 
  Net cash used in operating activities
    
(319,982
)
  
(204,423
)
  
(185,631
)
  
(141,625
)
Cash flows from investing activities
                  
  Purchases of fixed assets
   
(13,500
)
  
(13,500
)
  
(13,500
)
  
(13,500
)
  (Increase) decrease in restricted cash
    
340,407
   
(8,542
)
        
  Net cash used in investing activities
    
326,907
   
(22,042
)
  
(13,500
)
  
(13,500
)
 
                  
Cash flows from financing activities
                  
  Increase in due to affiliated companies
    
306,710
   
243,560
   
175,375
   
106,423
 
  Increase in loans payable - officers/directors
   
55,000
   
55,000
   
50,000
     
  Proceeds from sale of stock
    
85,000
   
85,000
   
85,000
   
85,000
 
  Payments on notes and loans payable
    
(482,587
)
  
(183,237
)
  
(137,717
)
  
(55,662
)
  Net cash provided by financing activities
    
(35,877
)
  
200,323
   
172,658
   
135,761
 
 
                  
Net increase (decrease) in cash
    
(28,952
)
  
(26,142
)
  
(26,473
)
  
(19,364
)
Cash, beginning of period
    
29,443
   
29,443
   
29,443
   
29,443
 
Cash, end of period
  
$
491
  
$
3,301
  
$
2,970
  
$
10,079
  
 
                  
F-30



20. Selected Quarterly Financial Data - 2005 (Unaudited)
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
Univec, Inc. and Subsidiaries
  
 
  
 
  
 
  
 
  
Statement of Cash Flow
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
Year Ended
  
 Nine Months Ended
  
 Six Months Ended
  
 Three Months Ended
  
 
  
December 31, 2004
  
 September 30, 2004
  
 June 30, 2004
  
 March 30, 2004
  
   
 (As Restated)
  
 (As Restated)
  
 (As Restated)
  
 (As Restated)
  
                       
Cash flows from operating activities
  
 
  
 
  
 
  
 
  
Net loss
    
($4,020,536
)
  
($1,712,250
)
  
($885,475
)
  
($493,106
)
Adjustments to reconcile net loss to net cash
                  
  used in operating activities
                  
  Loss on write-off of goodwill
    
1,774,119
                   
  Loss on sale of subsidiary
    
481,719
   
489,316
             
  Depreciation and amortization
    
189,008
   
135,686
   
91,135
   
45,938
 
  Write-off equipment
    
57,295
                    
  Valuation allowance for inventories
    
75,000
                    
  Stock based compensation
    
4,000
                   
  (Gain) on cancellation of capital lease
   
(2,894
)
                  
  (Gain) on extinguishment of debt
    
(98,547
)
  
(80,594
)
  
(40,040
)
  
(40,040
)
  Gain on receipt of marketable securities
    
(36,349
)
                  
  Other
    
(11,435
)
                  
Changes in assets and liabilities, net
                  
  Accounts receivable
    
(506,983
)
  
(367,110
)
  
(235,611
)
  
(199,313
)
  Inventories
    
17,698
    
2,904
   
(10,198
)
  
(3,533
)
  Other current assets and other assets
    
(3,320
)
  
(104,130
)
  
51,338
   
28,332
 
  Accounts payable and accrued expense
    
713,610
    
674,430
    
306,120
    
228,872
  
  Deferred payroll
    
619,631
   
440,840
   
496,793
   
299,497
 
  Net cash used in operating activities
    
(747,984
)
  
(520,908
)
  
(225,938
)
  
(133,353
)
Cash flows from investing activities
                  
  Purchases of fixed assets (net)
    
(397,068
)
  
(397,068
)
            
  (Increase) in restricted cash
    
(340,407
)
  
(335,000
)
  
(335,000
)
    
  Cash used in sale of subsidiary (net)
    
(5,670
)
  
(92,977
)
            
  Net cash used in investing activities
    
(743,145
)
  
(825,045
)
  
(335,000
)
  
0
  
 
                  

 
 
F-31




Cash flows from financing activities
 
 
 
 
 
 
 
 
 
 
 
 
 
  Proceeds from loans payable (net)
    
1,104,344
    
1,184,623
    
140,585
        
  Increase in due to affiliated companies
 
 
567,193
 
 
270,883
 
 
429,693
 
 
92,283
 
  Increase in loans payable - officers/directors
 
 
54,000
 
 
54,000
 
 
54,000
 
 
54,000 
 
  Proceeds from sale of stock
 
 
50,000
 
 
              
 
  Payments on notes and loans payable
 
 
(242,386
)
 
(167,350
)
 
(25,999
)
 
(23,899
)
  Payments of capital lease obligations
 
 
(21,232
)
 
                
  Dividends converted to preferred stock
 
 
(3,168
)
                  
  Net cash provided by financing activity
 
 
1,508,751
  
 
1,342,156
 
 
598,279
 
 
122,384
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net increase (decrease) in cash
 
 
17,622
  
 
(3,797
)
 
37,341
  
 
(10,969
)
Cash, beginning of period
 
 
11,821
 
 
11,821
 
 
11,821
 
 
11,821
 
Cash, end of period
 
$
29,443
 
$
8,024
 
$
49,162
 
$
852
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The year ended December 31, 2005 and 2004, including all quarterly periods within those years, financial statements have been restated to properly reflect the revenues and related cost of revenues from its Group Purchasing Operation (GPO) and physician sampling programs. The Company has restated the revenue and cost of revenue from these activities to the “net” method of revenue recognition. Previously, the Company utilized the “gross” method of revenue recognition for such activities.

As a result of the differing circumstances related to the Company’s manufacture, procurement, distribution and physician sampling programs, diverse financial accounting methods are utilized to recognize the revenue from its various financial sources.
 
The Company utilizes the “gross” sales method of recognizing the amount of revenue from its syringe manufacturing and specialty pharmaceutical drug product sales. This method is influenced by several factors as defined by EITF 99-19, which the Company’s manufacturing and specialty pharmaceutical drug product sales market agreements indicate to be in accordance with the gross sales method. The most significant factor under these agreements include the Company’s retention of the inventory’s risk of loss for these products.

The GPO and physician sampling programs use the “net” method of revenue recognition. However, the Company rather than the supplier is the primary credit obligor in these arrangements.

The year ended December 31, 2005 Statement of Operations has been further restated to properly reflect $17,000 of general and administrative expenses which had originally been reported as cost of revenues.

 
F-32